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MicroRNAs (miRNAs) are a relatively newly discovered class of small endogenous non 
coding RNA molecules with important roles in cell function and cancer development. 
Mature miRNAs bind to complementary sequences of transcripts and either cleave or inhibit 
translation of the mRNA. Some studies have indicated that grouping of tumor samples based 
on miRNA expression profiling correlate better than mRNA expression with cell 
differentiation and development. Experiments with diagnostic profiling using miRNAs have 
lead to suggestions for the use of miRNAs in cancer therapy. The properties of the binding 
between the target mRNA sequence and the miRNA however, are complicated and diverse 
and available computer programs designed to predict miRNA targets uses different 
algorithms and often disagrees in their predictions. This emphasizes the need for 
experimental verification of putative binding sites, predicted by such algorithms. The aim of 
this thesis was to construct a vector system for functional miRNA target verification with 
EGFP as the reporter gene. Flow cytometry was chosen as the method for analysing the 
EGFP expression of transfected cells. The results verified the construction of five vectors: 
the constructed pmiRPG and four constructs with the 3‟UTR sequence from KRAS, WWOX, 
CXXC4 and WDR79 inserted in a fusion transcript with the EGFP gene. The results 
presented may indicate that a promoter exchange from a phosphoglycerate (PGK) promoter 
to a stronger promoter could enhance the fluorescence intensity of transfected cells and give 
better recordings. The flow cytometry analysis in the current thesis may indicate that the 
miRNA hsa-let-7a regulates the KRAS gene and that hsa-miR-487 regulates the WWOX gene. 
However an optimalization of the miRNA target verification system should be performed 
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MicroRNAs (miRNAs) are a class of small (~18-25 nucleotides) endogenous non coding 
RNA molecules that regulate a wide array of developmental and physiological processes 
(reviewed by Tong et al. (2008) and Mirnezami et al (2009)). One of the first miRNAs 
discovered, lin-4, initially termed an stRNA (short temporal RNA), was found in 
Caenorhabditis elegans, and was revealed to play an important role in the processes in the 
transition from larva to adult stage (Lee et al., 1993). A second miRNA, Let-7 first identified 
in C.elegans as a temporal switch between larval and adult fates (Reinhart et al., 2000), was 
subsequently identified in a large number of species, including vertebrates. Thousands of 
miRNAs have now been identified and 851 human miRNAs have been registered in the 
online database, miRBase (Welcome Trust Sanger Institute: http://microrna.sanger.ac.uk/, 
Release 13.0, March 2009) that gathers miRNA sequences (Griffiths-Jones, 2004; Griffiths-
Jones et al., 2006; Griffiths-Jones et al., 2008). These miRNAs are predicted to regulate the 
expression of over one third of all human genes (Lewis et al., 2005) and have been shown to 
be involved in a variety of biological processes such as developmental timing, cell death, cell 
proliferation and patterning of the nervous system (Bartel, 2004). 
miRNA genes are scattered across all chromosomes in humans except for the Y chromosome 
and approximately half of all known miRNAs is found in polycistronic clusters of often 
related, but sometimes unrelated miRNAs (Kim and Nam, 2006). Analyses of miRNA gene 
locations have showed that the majority of mammalian miRNA genes are located in defined 
transcription units (TUs) and can be categorized based on their genomic locations in introns 
of protein coding TUs, introns of noncoding TUs or exons of noncoding RNAs. An 
additional group are „mixed‟ miRNA genes present in either exons or introns depending on 
the alternative mRNA splicing pattern (Rodriguez et al., 2004).  
miRNAs are transcribed by the RNA polymerase II enzyme as long primary transcripts (pri-




5‟ and 3‟ end, respectively, and folded into one or more hairpin structures. The hairpin is 
processed (Figure 1-1) by a complex composed of the nuclear RNase III enzyme Drosha and 
the RNA binding cofactor Pasha/DGCR8 (Tang, 2005). The structure called precursor 
miRNA (pre-miR) is transported out of the nucleus and into the cytosol by exportin 5 and its 
cofactor Ran-GTP, and further processed by a second RNase enzyme, Dicer, which crop the 
hairpin into a short miRNA duplex (Tang, 2005). A helicase will unwind this duplex 
(Salzman et al., 2007) before it is cleaved into a mature miRNA and incorporated into an 
RNA-induced silencing complex (RISC) (Meister and Tuschl, 2004). The miRISC effector 
complex, containing an Argonaut protein as the catalytic component (Tang, 2005), is guided 
to complementary sequences in mRNA transcripts and regulate post transcriptional gene 
expression by translational repression of mRNAs that bind to miRNA with imperfect 
complementarity, or by cleavage of mRNA targets that bind to miRNA with perfect sequence 
complementarity (Tong and Nemunaitis, 2008). Translational repression trough sites in 
3‟UTRs (untranslated regions) is considered to be the predominant mechanism in 
mammalian cells (Brennecke et al., 2005; Sethupathy et al., 2006; Tang, 2005). 
 
Figure 1-1: miRNA processing. 
Nucleus: A primary miRNA (pri-miRNA) 
is transcribed from DNA, processed 
and folded into the pri-miRNA hairpin 
structure which is cleaved by a 
microprocessor complex. The shorter 
stem loop, pre-miRNA, is transported 
across the nuclear membrane. 
Cytoplasm: The pre-miRNA is further 
processed by Dicer, cropped into a 
short miRNA duplex and unwound. 
After cleavage, the mature miRNA are 
incorporated into an RNA-induced 
silencing complex (RISC). The miRNA-
RISC complex negatively regulates post 
transcriptional gene expression by 
translational repression or cleavage of 
the target mRNA dependent on the 
degree of complementarity. Figure 
from Tong et al. (2008). 
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1.2 miRNA in cancer 
1.2.1 miRNA as oncogenes or tumor suppressors 
Cancer arises from a stepwise accumulation of genetic alterations that drive the progressive 
transformation of normal human cells into highly malignant derivatives (Figure 1-2). The 
process has several steps that result in those alterations in cell physiology that lead to 
malignant cell growth, such as self sufficiency in growth signals, insensitivity to anti-growth 
signals, evasion from apoptosis, unlimited replicative potential, sustained angiogenesis, and 
tissue invasion and metastasis (Hanahan and Weinberg, 2000).  
 
miRNA expression correlates with various cancers, and some miRNAs are thought to 
function as tumor suppressors or oncogenes (reviewed by Esquela-Kerscher (2006)). One of 
the first examples of miRNA involvement in human cancer came from molecular studies 
characterizing the 13q14 deletion in human chronic lymphocytic leukaemia (CLL), which 
revealed that two miRNAs, miR-15a and miR-16-1, were the only genes within the smallest 
common region of deletion. The same miRNAs were found down regulated in over half of 
the human CLL-patients in one study (Calin et al., 2002). 
Studies show that neoplasies have distinct miRNA signatures that are tissue specific and 
differ from those of the normal tissue counterpart (Bottoni et al., 2007; Iorio et al., 2005; Liu 
et al., 2004; Lu et al., 2005; Volinia et al., 2006; Yanaihara et al., 2006). In most cases, 
deregulation consistently acts in one direction, either up regulating or down regulating the 
Figure 1-2: The six abilities indicated 
are suggested to be essential in the 
transformation from normal to 
malignant cells. The abilities may be 
acquired in various chronological 
orders in order to become 






miRNAs, which may suggest that these miRNAs play an important role in tumorigenesis 
(Negrini et al., 2007).  
miRNAs functioning as oncogenes are expected to have increased expression in tumors. 
These oncogene miRNAs usually promote tumor development by inhibiting tumor 
suppressor genes and genes that control cell differentiation and apoptosis. Many miRNA 
genes have been found that are significantly over-expressed in different cancers, and a large 
fraction of them appear to function as oncogenes (Zhang et al., 2007). The seven miRNAs on 
the polycistronic miR-17-92 cluster (miR-17-5p, miR-17-3p, miR-18a, miR-19a, miR-19b-1 
miR-20a and miR-92-1) are examples of oncogenic miRNAs, and are located on 
chromosome 13q31, a locus that is amplified in several kinds of lymphomas and solid 
tumors (Hayashita et al., 2005; Ota et al., 2004). Compared to normal tissue, the expression 
of the miR-17-92 cluster is significantly increased in aggressive forms of lymphomas, small-
cell lung cancer and human B-cell lymphoma, and it also appears to enhance lung cancer 
growth (Hayashita et al., 2005). Bioinformatic studies have indicated that numerous genes 
are targets of the miRNAs in the mir-17-19 cluster (Krek et al., 2005; Lewis et al., 2005). 
Examples are the tumor suppressor genes PTEN and RB2  (Lewis et al., 2003) and the cell 
cycle transcription factor E2F1(O'Donnell et al., 2005). 
miRNAs that are considered as tumor suppressor genes (TSG) often show decreased 
expression in some cancerous cells. Tumor suppressor miRNAs usually prevent tumor 
development by inhibition of oncogenes and genes that control cell differentiation or 
apoptosis (Zhang et al., 2007). Several miRNAs are considered as TSG, for example miRNA 
let-7, one of the first miRNAs to be discovered (Bartel, 2004).  Inappropriate expression of 
let-7 results in oncogenic loss off differentiation, and in humans, let-7 is located on a fragile 
chromosome region that usually are deleted in human cancers (Calin et al., 2004). Studies 
have shown that the RAS family of proteins which acts as regulators of cellular growth and 
diffrentiation, are direct targets of the let-7 family. Let-7 binds to the 3‟UTR of RAS and 
negatively regulates the gene expression by translational repression (Johnson et al., 2005). 
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1.2.2 miRNA in diagnostic profiling 
Grouping of tumor samples based on miRNA profiling has been shown give a better 
correlation than mRNA expression profiling, with cell differentiation and development (Iorio 
et al., 2008) and miRNA microarray analysis and northern blotting indicates that miRNA 
expression profiles are good indicators for distinguishing even poorly differentiated tumour  
tissues apart from normal tissues (Lu et al., 2005). These findings suggest that miRNAs can 
be used as biomarkers for malignancy in humans and could be powerful diagnostic tools to 
classify tumors and to predict outcome and prognosis. 
Various methods have been developed to classify tumors with regard to their miRNA 
expression, and to investigate the link between miRNA expression and cancer development 
and prognosis in humans. One of the first breast cancer specific miRNA signatures was 
obtained after a genome wide miRNA expression analysis on a large set of normal and tumor 
breast tissues (Iorio et al., 2005). In the same study, there were also identified miRNAs 
whose expression correlated with specific cancer biopathologic features such as expression 
of estrogen and progesterone receptor, tumor stage, vascular invasion or proliferation index 
(Iorio et al., 2005). 
Microarray assays using the entire available miRNAome have been developed and are widely 
used for miRNA expression analysis (Liu et al., 2004; Volinia et al., 2006). A bead based 
flow cytometry technique has also been used to evaluate the miRNA profiling in different 
tumor subtypes (Lu et al., 2005). Metastatic cancer of unknown primary origin is often a very 
aggressive disease with poor prognosis (Pimiento et al., 2007) and Rosenfeld et al.(2008) 
developed a miRNA based tissue classifier system as a tool to classify the origin of tumor 
samples. The system was based on 48 distinctly expressed miRNAs and the classifier 
algorithm was constructed as a branched binary tree that was able to distinguish between 25 
different types of cancers (Rosenfeld et al., 2008).  
miRNAs can predict the clinical behaviour of certain cancers. Reduced expression of let-7 
family members has, as an example been shown to correlate with reduced survival in lung 
cancer, and also shorter overall survival after curative surgery, independent of the disease 




relationship between overexpression of miR-155 and poor post operative survival in lung 
cancer and B-cell lymphomas, suggesting that miR-155 may act as a predictor for aggressive 
tumor phenotypes (Calin et al., 2005; Yanaihara et al., 2006). 
1.2.3 miRNA in future cancer therapy 
Synthetic anti-sense oligonucleotides that encode sequences that are complementary to pri-, 
pre- or mature- miRNAs are called AMOs (anti-miRNA oligonucleotides). AMOs might be 
used to inactivate oncogenic miRNAs in tumors and slow down tumor growth (Weiler et al., 
2006). AMOs that are conjugated with cholesterol, called “antagomirs”, have been shown to 
effectively inhibit endogenous miRNA activity in various organs when injected into mice, 
and might be promising therapeutic agents  (Krutzfeldt et al., 2005).  
 miRNA inactivation could alternatively be accomplished through frequent or continuous 
delivery of antisense oligonucleotides such as 2‟-O-methyl- or locked nucleic acid (LNA 
modified nucleotides), which are specially designed to be more stable and less toxic than 
other cancer treatments in order to target transforming miRNAs such as miR-155 (Meister et 
al., 2004). 
Transient expression systems that use viral or liposomal delivery might be useful for in vivo 
administering of large quantities of miRNAs such as the tumor suppressor family let-7. 
These techniques would involve expression of the pre-miRNA hairpin and flanking 
sequences, potentially under the control of tissue specific promoters (Esquela-Kerscher and 
Slack, 2006).  
miRNAs could likely influence the response to chemotherapy or targeted therapies such as 
Trastuzumab, a monoclonal antibody against HER2, or anti-estrogens such as Tamoxifen by 
making the cells more vulnerable. miR-21, which directly targets the oncosuppressor PTEN, 
has been demonstrated to influence the response to chemotherapy, in particular gemcitabine 
(Meng et al., 2006). The let-7 family can suppress the resistance to anticancer radiation 
therapy and thereby alter the sensitivity to radiation (Weidhaas et al., 2007). 
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1.3 miRNA-mRNA interaction 
1.3.1 miRNA target binding 
miRNA target sites in the 3‟UTR sequences of mammalian mRNAs can be divided into three 
categories with different binding properties (Figure 1-3). Targets with “5‟ dominant” sites 
base pair well to the 5‟end of the miRNA binding site. Subtypes of this group are the 
“canonical” sites which pair well at both 3‟ and 5‟ ends of miRNAs, and “seed” sites which 
require little or no 3‟ end pairing support. Target sequences in the second group, “3‟ 
compensatory” sites have weak 5‟ base pairing and depend on strong compensatory binding 
in the 3‟ end of the miRNA (Brennecke et al., 2005). 
 
Figure 1-3: Three categories of miRNA target sites. Experimentally supported examples of mammalian miRNA 
target sites; canonical (left), seed (middle) and 3’ compensatory (right). Figure from Sethupathy et al. (2006). 
The most important element in miRNA binding is the ”seed” sequence in the 5‟ region of the 
miRNA, centred on nucleotides 2-7, that bind to the mRNA sequence with Watson-Crick 
pairing. Use of seed match as a criterion for miRNA target site search, markedly reduces the 
occurrence of false positive predictions (Brennecke et al., 2005; Krek et al., 2005; Lewis et 
al., 2003) and improves prediction reliability (Lewis et al., 2003). Experiments have also 
showed that miRNA-like regulation was most sensitive to nucleotide substitutions that 
disrupted seed pairing (Brennecke et al., 2005). 
In addition to the seed binding, there are numerous potential pairing possibilities involving 
the 3‟end of the miRNA and the UTR. The “3‟supplementary” sequences optimally centres 




The association is sensitive to pairing geometry, and prefers at least 3-4 contiguous Watson-
Crick pairs uninterrupted by bulges, mismatches or wobbles. This type of binding however, 
is atypical and plays only a modest role in target recognition (Grimson et al., 2007). 
“3‟compensatory” sequences of miRNAs can compensate for a single nucleotide bulge or 
mismatch in the seed region. The pairing of the 3‟ compensatory sequences centred on 
miRNA nucleotides 13-17 extends to at least nine contiguous Watson-Crick pairs. Extensive 
pairing to the 3‟end of the miRNA however, is not sufficient to confer regulation on its own 
without a minimal element of complementarity in the 5‟end (Brennecke et al., 2005). 
The efficiency in which the miRNAs bind to the target mRNAs ranges from efficient binding 
with an 8mer seed sequence to marginal binding with a 6mers seed. Dual binding of the seed 
sequence in combination with compensatory or supplementary binding such as a 7mer-8mer 
or two 7mers are also considered efficient (Bartel, 2009). 
A “seed nucleation” model (Figure 1-4) proposes how binding of the miRNA to the mRNA 
3‟UTR is nucleated at the seed match, spreads to the central and 3‟ regions of the miRNA 
and leads to repression of translation ,or less common cleavage of miRNA (Bartel, 2004, 
2009). miRNAs bound to Argonaut proteins are organized to favour recognition and pairing 
to 8mer sites in the mRNA, by a binding pocket. An A at position 1 of the site is recognized 
directly by proteins of the silencing complex. Massive conformational accommodation 
(Figure 1-4c) of extensive paired sites leads to pairing, anchoring and nucleation at the seed. 
The seed nucleation extends to the central region of the miRNA and causes the protein to 
loosen its grip on the 3‟region of the miRNA, and thereby allows the miRNA and mRNA to 
wrap around each other. This pairing can lead to mRNA cleavage when the Argonaut protein 
locks down on the paired duplex. 3‟supplementary pairing can lead to translational 
repression (Figure 1-4e) when the mRNA pairs to nucleotides 13-16 and incorporates them 
into a short helical segment. In this mode of recognition however, the miRNA and mRNA 
are not wrapped around each other (Bartel, 2009). 
 




Figure 1-4: Speculative “Seed nucleation” model. a) miRNA (red) bound to Argonaut (AGO) protein (grey) 
favour pairing to an incoming mRNA strand (blue). b) Recognition of 8mer site by the binding pocket c) 
Conformational changes cause the protein to loosen its grip on the 3’region of the miRNA, allowing the miRNA 
an mRNA to wrap around each other. d) The Argonaut protein locks down on the paired duplex, which places 
the active site in position (arrow head) to cleave the mRNA. e) The mRNA can pair to nucleotides 13-16, 
incorporating them into a short helical segment in a 3’supplementary pairing which leads to translation 
repression. Figure from Bartel et al. (2009). 
The location of sites within the 3‟UTR sequence can have a positive influence and enhance 
the effect of miRNA binding. The position of the miRNA binding site in the 3‟UTR is 
reported to be more conserved and more effective when located 15 nucleotides or more after 
the stop codon (Grimson et al., 2007) and a genome wide analysis of site conservation, site 
efficiency and site depletion indicated that sites tend to be most effective if they do not fall in 
the middle of a long UTR sequence (Grimson et al., 2007). The same analysis also showed 
that the nucleotides in the immediate vicinity of the site are important, and sites within a 
region of high local AU content were performing best. The authors discovered that sites 
close together (within 40nt and minimum 8nt apart) tend to act cooperatively, leading to 
enhanced repression over that expected from two separate sites (Grimson et al., 2007). 
miRNA activity can be classified according to different effects on the protein level, 
phenotype or number of target sites, and the regulatory effects on the target transcript are 
diverse and complex (reviewed in Flynt (2008)). A summary is presented in Figure 1-5. 
When assaying at the protein level, the “switch targets” are turned off by miRNAs. “Tuning 
targets” in contrast remain functional but reduced in quality, and neutral targets have no 
consequence on the protein level. The intrinsic detectable miRNA contribution to 




in phenotype. miRNA regulation can also be classified according to whether a major effect is 
mediated through one or a few target sites or many targets (target battery). All known 
switches concern cases of one or a few important miRNA target sites (Flynt and Lai, 2008). 
 
Figure 1-5: Classification of miRNA activity and function. a) Targets that become inactive following miRNA 
mediated repression are called “Switches”, whereas “tuning” targets continue to produce functional proteins 
in reduced amounts. Neutral targets have no consequence for the cell, and are possibly species specific. b) 
Targets with genetically defined and phenotypic consequences are called “miRNA genetic switches”. Other 
targets only have fine tuning or auxiliary effects c) The total number of targets who are repressed by miRNA 
can be detected quantitatively for a given effect. Genetic switches are regulated through only one or a few 
targets. Detectable effects can also originate from the combination of hundreds of regulated targets. Figure 
from Flynt et al. (2008). 
1.3.2 Identification of miRNA targets 
The parameters that are important for efficient miRNA target recognition and specificity are 
still not fully understood, and the available tools for miRNA target predictions do not always 
agree on which miRNAs that bind to a given target sequence. 
Watanabe et al. (2007) presented a schematic summery in the form of a pipeline of common 
algorithms used in the prediction of miRNA targets (Figure 1-6). The first step is the 
extraction of orthologous miRNA and mRNA 3‟UTR sequences. The base pairing between 
miRNAs and their targets can be analyzed next, to check for features such as stable binding 
at the 5‟ end of the miRNA. Thermodynamic analysis of miRNA-mRNA duplexes is 
performed calculating the free energy of the duplex formation and binding. Cross species 
sequence comparison is used to investigate the evolutionary conservation between related 
species. The number of target site for the miRNA can be counted as a final step, since 
mRNAs are likely to be regulated by miRNA binding to more than one target sites 
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(Rajewsky, 2006; Watanabe et al., 2007). The programs used for miRNA target predictions 




The miRNA registry, miRBase (Griffiths-Jones, 2004; Griffiths-Jones et al., 2006; Griffiths-
Jones et al., 2008) includes information about the potential genomic targets of miRNAs in 
addition to the miRNA sequence data. The miRBase Target database thereby provides 
predicted miRNA target transcripts for various species with the use of the database and the 
miRanda algorithm. The miRanda software was initially designed to predict miRNA targets 
Figure 1-6: A schematic pipeline for the 
main steps in miRNA target predictions: 
Datasets from miRNAs and mRNAs (3’UTR) 
are provided for input and similar datasets 
from related species are constructed using 
data on putative orthologs. Preparations 
of the datasets leads to the identification 
of miRNA binding sites through four steps: 
1) Determination of base pair patterns 
according to the complementarity within 
specific regions. 2) Determination of the 
strength of the miRNA-mRNA duplex by 
calculation of the free energy. 3) 
Comparative analysis. 4) Check for the 
presence of multiple target sites per 
mRNA transcript.  Figure from Watanabe 





in Drosophila melanogaster but has also been applied to predict human miRNA targets 
(Enright et al., 2003; John et al., 2004). The algorithm uses three steps starting with the 
identification of a potential target sequence. The free energy is calculated for the miRNA-
mRNA duplex and in the final step, the evolutionary conservation are established (Enright et 
al., 2003; John et al., 2004). 
TargetScan is an algorithm developed for prediction of miRNA targets in vertebrates (Lewis 
et al., 2003) and the TargetScanS is an improved algorithm which requires a shorter seed 
match (six nucleotides) and is independent of thermodynamic stability or multiple target 
sites. The algorithm requires the presence of conserved adenosines around the seed sequence 
(Lewis et al., 2005). 
The DIANA-microT computational program uses the necessity of a central bulge and strong 
binding at the 3‟ end of the miRNA, when the 5‟ seed pairing is weak. This method uncovers 
predominant miRNA targets that contain only single target sites (Kiriakidou et al., 2004). 
The PicTar software fully relies on comparative data from several species to identify 
common targets for miRNAs (Krek et al., 2005). The likelihood that a given sequence is 
bound by one or more miRNAs is estimated and the target genes are predicted using a 
common criteria, such as optimal binding free energy. The site is then tested statistically 
using genome wide alignment of eight vertebrate genomes to filter false positives (Krek et 
al., 2005). 
In this study the programs showed a wide variation of miRNA target predictions. The few 
times they agreed, there were seldom more than two programs that predicted the same 
miRNA for a specific gene. This emphasizes the need for experimental verification of 
putative miRNA binding sites. The approach chosen in the present study was to select 
miRNAs that were predicted by two or more programs to target a chosen transcript, and use 
them in cotransfections with a reporter vector. The miRNAs selected for each of the genes 
are listed in Table 3-3. 
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1.4 Project background 
1.4.1 Choice of method 
There are several vectors and assays available for miRNA target analysis, and the common 
feature of these systems is the use of a gene encoding a luciferase protein that produce light 
through a chemical reaction (Marques and Esteves da Silva, 2009). The light produced and 
recorded directly from the whole cell population is used as a measure of the level of gene 
expression. The values represent the average intensity of all cells.  
In this thesis the idea was to use enhanced green fluorescent protein (EGFP) a mutated 
(Heim et al., 1995; Patterson et al., 1997) version of GFP from the jellyfish Aqueorea 
Victoria (Prasher et al., 1992) as the reporter gene in the expression vector. EGFP emits 
green light (fluorescence) when exposed to ultra violet light, and can be analysed by flow 
cytometry. The advantage using this approach is that it is possible to discriminate between 
transfected and nontransfected cells, and to record and compare fluorescence intensity from 
single cells in the transfected population of cells.  
To our current knowledge, there are no vectors available for miRNA target analysis that use 
EGFP as the reporter gene, and consequently, an expression vector for this thesis using 
EGFP had to be constructed. 
1.4.2 Genes for cloning into the reporter vector 
1.4.2.1 KRAS 
KRAS (GenBank: M54968) is one of the founding members of the RAS (rat sarcoma) 
superfamily of small GTPases (reviewed in Quinlan et al. (2009)). This family of proteins 
contains master regulators of a wide range of cellular processes including growth, 
proliferation, survival, apoptosis, senescence, cytoskeletal dynamics, vesicular trafficking, 
differentiation and gene expression (Giehl, 2005; Malumbres and Barbacid, 2003; 




The RAS genes are frequently mutated in human cancer and it is estimated that 
approximately 15-20% of all human tumors have activating mutations in one of the RAS 
oncogenes or components of the Ras signalling pathway. Several approaches are made to 
develop tumor therapies effectively targeting RAS and RAS effector pathways (Adjei, 2001; 
Downward, 2003). 
The family of RAS genes has been shown to be regulated by miRNAs and the let-7 miRNA 
has a documented strong effect on the regulation of the KRAS gene. Let-7 binds to the 
3‟UTR sequence of KRAS mRNA and effectively reduces the expression of KRAS (Johnson 
et al., 2005). The KRAS 3‟UTR sequence was included in this thesis primarily as a positive 
control that would be valuable for the verification of the functionality of the miRNA binding 
site reporter system. 
1.4.2.2 CXXC4 
CXXC finger 4 (CXXC4, GenBank: NM_025212) encodes the protein called Idax (Inhibition 
of the Dvl and Axin complex) which acts as a negative regulator of the Wnt signalling 
pathway by interacting with Dishevelled (Dvl)(Hino et al., 2001).  
Kojima et al. (2009)showed that CXXC4 mRNA levels in tumor samples were significantly 
lower in patients with metastases compared to those without, and in addition, patients with 
poor cause-specific survival outcome showed decreased CXXC4 expression. Decreased 
CXXC4 expression has been linked to aggressive renal cell carcinoma (RCC) (Kojima et al., 
2009). Knockdown experiments have revealed that the lowered CXXC4 expression leads to 
activation of the Wnt/ β-catenin signalling and thereby promotes cell proliferation and 
survival in RCC cells. The 3‟UTR sequence from this gene was chosen for study in this 
thesis because miRNAs may be a factor involved in the downregulation of this gene. 
1.4.2.3 WDR79 
 WD repeat domain 79 (WDR79, GenBank: NM_018081), also called WRAP53 (WD repeat 
containing, antisense to TP53) codes for a protein that belongs to the large WD-repeat 
protein family with diverse functions (Smith et al., 1999) and has recently been associated 
with Cajal body-specific RNPs (scaRNPs) and with telomerase RNA (Tycowski et al., 2009) 
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WDR79 is transcribed in an antisense orientation relative to the tumor suppressor gene 
TP53, thus juxtaposing proximal promoter elements between these two genes. The WDR79 
transcript could include regulatory elements for the transcription of TP53 mRNA (Laitinen et 
al., 2004)  
Garcia-Closas et al. (2007) revealed a linkage disequilibrium (LD) between TP53 and its 
flanking gene WDR79, and their data suggested that common variants in regulatory regions 
of TP53 and WDR79, could be related to increased risk for development of ER negative 
breast cancer (Garcia-Closas et al., 2007). This gene is interesting due to its relation to the 
widely known tumor suppressor gene TP53, and was therefore chosen for studies of potential 
miRNA binding to the 3‟UTR sequence. 
1.4.2.4 WWOX  
The WW domain-containing oxidoreductase gene (WWOX, GenBank: AF211943) contains 
nine exons, and encodes an mRNA that is 2.2kb long. The gene is located on chromosome 
16q 23.3-24.1 in a region recognized as the fragile site, FRA16D (Bednarek et al., 2000). 
WWOX might play a central role in different signal transduction pathways and a number of 
cellular processes including transcriptional repression, growth and apoptosis (Aqeilan and 
Croce, 2007). Studies have shown that WWOX expression is up regulated in endocrine 
organs such as testis, ovary and breast, indicating the importance of WWOX in these tissues 
(Bednarek et al., 2000).  
Studies demonstrate that WWOX expression is lost or reduced in a variety of human 
malignancies making WWOX the fragile gene target of genomic alterations at 16q23 (Ludes-
Meyers et al., 2003). The frequent deletions of WWOX  in multiple tumors suggest that it 
may act as a tumor suppressor gene involved in a variety of cancers like breast, ovarian, 
prostate, esophageal, lung, gastric and hepatic (Hezova et al., 2007). Over-expression studies 
indicates that the gene might be capable of suppressing tumor growth, and ectopic expression 
of WWOX has been shown to strongly inhibit anchorage independent growth of several breast 




In a mutation screen of the coding region of the WWOX gene in a breast cancer cell panel, no 
evidence of mutation within the nine exons of the WWOX gene was detected (Bednarek et 
al., 2000; Driouch et al., 2002).Thus the mechanisms responsible for the downregulation of 
WWOX in cancers are unclear. In this thesis we aim at testing if candidate miRNAs regulate 
WWOX expression through binding to the WWOX 3‟UTR. 
1.5 Aims of the thesis 
In the present study, the aim was to construct a reporter vector system for functional 
verification of miRNA binding sites. The vector includes EGFP as the reporter gene. The 
following aims were pursued in this thesis. 
1. Construction of the vector. 
2. Cloning of the 3‟UTR sequences of the selected genes into the vector. 
3. Use of online miRNA target prediction programs to predict miRNAs for the selected 
genes. 
4. Use of flow cytometry to analyse changes in the EGFP expression levels when a 
human cell line is cotransfected with the vectors and miRNAs. 
      Material and methods 
27 
 
2 Material and methods 
This chapter presents materials and methods used in the thesis. Solutions were made 
according to Sambrook et al.(2001), if nothing else is specified. 
2.1 Microbiological techniques 
2.1.1 Medium and Agar preparations 
LB medium and LB agar were made according to standard protocols (Sambrook and Russel, 
2001), and autoclaved immediately after preparation to achieve sterilization and to dissolve 
the solid reagents. The media and agar were stored at 4°C and preheated to 37°C before use 
with E.coli bacteria. 
Selective LB media and LB agar were made to select for bacteria transformed with plasmids 
containing a gene for antibiotic resistance.  
LB agar plates were made using a microwave oven to melt the agar. The agar was cooled 
down to approximately 50°C. When acquired for selection, ampicillin (Sigma-Aldrich, St. 
Louis, MO, USA) was added to a final concentration of 100µg/ml and 15ml melted LB agar 
was transferred to each Petri dish and cooled down to solidify. The LB agar plates were 
stored at 4°C. 
2.1.2 Growth and storage 
The E.coli strain DH5α (Invitrogen, Carlsbad, CA, USA) was used for cloning experiments 
and for general selection and amplification of plasmid DNA. Transformed bacteria were 
streaked onto selective LB-agar plates and incubated overnight at 37°C to obtain single 
colonies. Colonies were inoculated in separate selective LB-medium and incubated at 37°C 
overnight with agitation of 225 rpm in a Minitron Incubator Shaker (Infors AG, Bottmingen, 
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Switzerland). For prolonged storage, glycerol stocks were made from overnight bacterial 
cultures mixed with glycerol to a final concentration of 15% and stored at -80°C. 
2.1.3 Preparation of competent E. coli 
Competent bacteria were made according to the protocol from Inoue et al. (1990). A frozen 
stock of E. coli DH5α™ (Invitrogen, Carlsbad, CA, USA) was thawed and streaked out on 
non-selective LB-Agar plates and incubated over night at 37°C. The next day, a few colonies 
were inoculated in 250 ml SOB-medium in a sterile Erlenmeyer flask. The bacteria were 
incubated at 30°C with vigorous shaking. A spectrophotometer was used to register cell 
density. Incubation was stopped when the cell density reached OD600 = 0.6. The flask was 
chilled on ice for 10min and the cells were harvested by centrifugation at 6000 x g for 10min 
at 4°C. The cells were resuspended in 80ml ice cold TRB (10 mM Pipes, 15 mM CaCl2, 250 
nM KCl, 55 nM MgCl2), placed on ice for 10 min and centrifugated again under the same 
conditions. Next, the cells were resuspended in 20 ml TRB, and gently while stirring, 
Dimethyl sulfocside (DMSO) (Sigma-Aldrich, St. Louis, MO, USA) was added to a 
concentration of 7%. The cells were left on ice for 10 min. 500µl cell suspension was 
aliquoted in eppendorf tubes, and snap frozen in dry ice and ethanol. The competent cells 
were stored at -80°C. 
2.1.4 Heat shock transformation of E. coli 
Competent DH5α E. coli was transformed with plasmids containing genes for antibiotic 
resistance (Cohen et al., 1972) according to the protocol of Sambrook et al. (2001). A tube of 
500µl competent cells was thawed on ice, and aliquots of 50 µl were transferred to eppendorf 
tubes on ice. 1-5µl DNA solution was added and mixed gently into the cells with a pipette 
tip. As a control, 250 pg of pUC19 (Invitrogen, Carlsbad, CA, USA) was added in a separate 
tube. The transformation mixtures were incubated on ice for 30 min, heat shocked at 42°C in 
30 seconds, and placed back on ice for 2 min. The cells were transferred to 5ml tubes and 
added  950µl pre-heated (37°C) LB-media and incubated for one hour at 37°C, with agitation 
at 225 rpm in a Minitron Incubator Shaker (Infors AG, Bottmingen, Switzerland). The 
incubation allows the bacteria to recover and express the antibiotic marker encoded by the 
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plasmid. 100-500 µl of each transformation reaction was streaked on to pre-heated LB-Agar 
plates with 100µg/ml ampicillin (Sigma-Aldrich, St. Louis, MO, USA). The plates were 
incubated overnight at 37°C. 
The transformation frequency was calculated from the number of transformants on the 
pUC19 control-plate, divided by the amount of DNA added, in µg. 
2.2 DNA techniques 
2.2.1 Isolation of plasmid DNA 
Plasmids were isolated from E. coli using the QIAprep® Spin Miniprep Kit (Qiagen®, 
Hilden, Germany) according to the manufacturer‟s protocol. In short, bacterial pellets from 
5ml overnight cultures were resuspended and lysed under alkaline conditions. Sodium 
dodecyl sulphate (SDS) causes precipitation of cell debris which traps the genomic DNA. 
Plasmids however remain suspended.  The lysis reactions were neutralized and the 
supernatants were transferred to a provided column, where the plasmid DNA was absorbed 
onto a silica membrane. After necessary washing steps to remove endonucleases and salts, 
the DNA was eluted in 30-50µl elution buffer (Qiagen®, Hilden, Germany) for a total yield 
of up to 20µg of DNA (high copy plasmids). For bigger experiments QIAGEN Plasmid 
Midiprep Kit (Qiagen®, Hilden, Germany) was used to purify up to 100µg of DNA (high 
copy plasmids) from a 25ml culture. The method was similar to the Miniprep except for the 
last steps. After elution of the DNA from the column, the DNA was precipitated with 
isopropanol in combination with centrifugation. The resulting pellet was washed in 70% 
ethanol, air dried and resolved in 50 µl nuclease free water or TE-Buffer (Qiagen®, Hilden, 
Germany). Purified plasmids in solution were stored at -20°C or at 4°C for shorter periods. 
2.2.2 DNA precipitation 
Precipitation was used to purify DNA resolved in liquid (Sambrook and Russel, 2001). The 
solution containing DNA was mixed with 10% 3M Sodium Acetate and 2.5 times the 
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volume of 100% ethanol. The mixture was centrifugated at 15000 x g at 4°C for 30 minutes. 
The supernatant was removed, and an ample amount of 75% ethanol was added to wash the 
DNA properly. The tube was centrifugated again for 10 minutes. The supernatant was 
removed and the pellet was left to air-dry in room temperature. The dried DNA was 
resuspended in nuclease free water or Elution Buffer (Qiagen®, Hilden, Germany). To 
separate plasmids from oligo nucleotides, 0.6 volumes of isopropanol were used instead of 
ethanol to enrich for vector fragments relative to oligo nucleotides.  
2.2.3 Purification of DNA fragments from an Agarose Gel 
DNA fragments separated on an agarose gel (section 2.2.7) were cut out and purified using 
QIAqick
®
 Gel Extraction Kit (Qiagen
®
, Hilden, Germany). In short, the gel slice containing 
DNA fragments of 70bp-10kb was incubated at 50˚C with 3x volumes of a supplied buffer to 
melt and dissolve the gel. When the solution was homogenous (after approximately 10min), 
it was applied to a QIAqick column (supplied) and spun down to bind the DNA in the 
column. The DNA in the column was washed an additional time with the same buffer to 
remove all gel traces, and finally washed and eluted in the same way as with the QIAprep
®
 
Miniprep Kit protocol (see 2.2.1:Isolation of plasmid DNA). 
2.2.4 Quantification of DNA 
Quantification of DNA was done using NanoDropTM 1000 Spectrophotometer (Thermo 
Scientific, Wilmington, DE, USA) according to the manufacturer‟s user manual. In short, the 
buffer in which the DNA was resolved was set as blank, and one µl of undiluted DNA 
sample was applied to the instrument. The sample absorbance of UV-light with wavelength 
of 260nm was detected, and the concentration (ng/µl) was calculated according to Beer‟s 
Law. To additionally assess the purity of the DNA sample, a ratio of sample absorbance at 
260nm and 280nm was recorded. A 260/280-ratio of 1.8-1.85 was accepted as pure DNA. 
Values below may indicate the presence of proteins and values above may indicate presence 
of phenol or RNA. 
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2.2.5 Restriction enzyme digestion 
Restriction digestion of DNA, for analytical purposes, was prepared in a total reaction 
volume of 10 µl. 200-400ng of DNA was digested by 5-10 units of restriction enzyme. One 
unit (U) is defined as the amount of enzyme that digests 1µg DNA in one hour at optimal 
conditions. Appropriate buffer (10x concentration) and bovine serum albumin (BSA) (100x) 
provided by New England Biolabs (Ipswich, MA, USA) were diluted to a 1x concentration, 
and nuclease free water was used to attain the correct reaction volume. For a preparative 
restriction cutting, 2 µg of DNA and 10-20U of enzyme were used. The volume was adjusted 
to avoid more than 10% of enzyme volume in the total reaction volume. The enzymatic 
reaction was left on a heating block for one hour at the optimal temperature for the enzyme 
used. 
2.2.6 Dephosphorylation of DNA 
Dephosphorylation reactions were used to remove the 5‟-phosphate from linear DNA 
fragments. This was accomplished with use of the dimeric glycoprotein calf intestinal 
alkaline phosphatase (CIP) (NEB, Ipswich, MA, USA). Dephosphorylation was done to 
decrease incidences of vector re-circularization, in experiments where a vector and an insert 
sequence were digested with the same enzyme and ligated together. This is an efficient way 
to diminish vector background in cloning experiments. The CIP-reactions were carried out as 
recommended by the provider (NEB, Ipswich, MA, USA). Generally, 0.5U CIP enzyme was 
used per µg of DNA.  
2.2.7 Agarose gel electroforesis 
DNA fragments of 37bp-10kb were analyzed on an agarose gel using 1 X TAE buffer with 1-
2% SeaKem® LE agarose (Cambrex Bio Science, Rockland, ME, USA) added. Buffer and 
agarose powder were boiled to obtain a homogenous solution. After heating, the solution was 
cooled down to approximately 60°C and the SybrSafe® DNA gel stain (Invitrogen, Carlsbad, 
CA, USA) was added in an amount that diluted the 10 000 x solution to 1 x. Typically 5 µl 
Sybr Safe was used in 50 ml TAE. The solution with DNA fragments was added Gel 
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Loading Dye (NEB, Ipswich, MA, USA) (provided in a 6x concentration) to a final 
concentration of 1x. The solution contained 2,5% Ficoll 400 to increase the density of the 
sample, and trace amounts of SDS to remove enzymes remained bound to the DNA. The dye 
also contained EDTA that binds magnesium to stop enzymatic reactions. Bromophenol blue 
was the tracking dye and it migrate equivalent to a 300bp fragment on a 1% agarose gel. This 
made it possible to follow the migration through the gel, and thereby estimate when to stop 
the gel. The DNA fragments were separated according to their size and migrated towards the 
positive pole. A ladder sample with known fragment sizes was also loaded on to the gel for 
analytical purposes (NEB, Ipswich, MA, USA; Fermentas, Burlington, Ontario, Canada). 
UV-light with 254nm was used to detect the DNA fragments after ended electrophoresis. To 
visualize the smallest fragments 37bp-100bp, additional gel stain was added to the buffer a 
few minutes before the electrophoresis was ended. 
2.2.8 Ligation of DNA fragments 
Digested DNA fragments were ligated together with the use of bacteriophage T4 DNA ligase 
as recommended by the supplier (Roche™, Basel, Switzerland). The enzyme catalyzes the 
formation of phosphodiester bond between the 5‟phosphate end and the 3‟hydroxyl end in 
double stranded DNA. Generally, 100ng of the linear vector was used, and the molar ratio 
between the vector and the insertion fragments was set from 1:3 to 1:20 depending on the 
amount of DNA left after all preparative steps (digestion reactions, precipitation). The 
reaction volume was kept as small as possible (maximum 20µl), and 1U of enzyme was used 
per reaction. The reaction was incubated overnight at 16°C (sticky ends). 
2.2.9 Primer design 
Primers used in PCR or sequencing reactions were designed using the web based tool 
Primer3 (http://frodo.wi.mit.edu/). The DNA sequence of interest was specified and the 
program made suggestions for one or more primer pairs flanking the sequence. The primer 
estimations were made with fixed parameters including the GC content, primer length and 
melting temperature to ensure the quality of the primers. The oligo nucleotides were 
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purchased from MWG Biotech (Ebersberg, Germany). All primers used in this thesis are 
listed in the Appendix, Table 1. 
2.2.10 PCR Reaction 
Polymerase chain reactions (PCR) were used to amplify specific DNA fragments. A thermo 
stable polymerase was used for automated reaction cycles (Saiki et al., 1988). For this thesis 
VentR
®
 DNA polymerase (NEB, Ipswich, MA, USA) was used. This polymerase has high 
fidelity caused by the 3‟-5‟ proofreading exonuclease activity (Mattila et al., 1991). The 
optimal temperature was 72°C and the enzyme was stable at 95°C, the temperature used to 
separate double stranded DNA. The melting temperature was set 1°C below the estimated 
melting temperature of the primers, and the DNA polymerase extension time was set to 30 
seconds per 500bp. The program that was adjusted for each reaction was as follow: 2 min at 
95°C, followed by 30 cycles with 95°C denaturation for 30 sec, X°C annealing for 30 sec 
and 72°C extension for Y seconds. The reaction was prepared in PCR-tubes in 50µl total 
reaction volume containing 1U of the polymerase, 1x Vent buffer (NEB, Ipswich, MA, 
USA), 0.01mM of each primer and 10mM of dNTPs. 10ng of DNA template was added and 
the reaction was run in a GeneAmp
® 
PCR system 9700 (Applied Biosystems Inc, Foster City, 
CA, USA).  
2.2.11 Sequencing of DNA 
Sequencing was done to verify new DNA sequences in expression vectors. The method was 
carried out similar to the PCR reaction (2.2.10) with some important differences. The 
reactions were set up with forward and reverse primer in separate tubes. The nucleotide mix 
contained the four dNTP‟s and in addition a portion of ddNTP‟s labelled with four different 
fluorescent dyes. The dye labelled ddNTP‟s terminates the elongation and when they were 
incorporated randomly, multiple molecules of varying length were generated. 
In this thesis all sequencing experiments were done using the primers pmiRPG-5850-Fwr 
and pmiRPG-6136-Rev (Appendix, Table 1). BigDye® Terminator v 3.1 Cycle sequencing 
kit (Applied Biosystems Inc, Foster City, CA, USA) was used to prepare the sequencing 
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reaction according to the manufacturers instruction. Automated cycles were performed by the 
GeneAmp® PCR system 9700 (Applied Biosystems Inc, Foster City, CA, USA) and started 
with 1min of 96°C, followed by 25 cycles of 96°C denaturation for 10 sec, 50°C annealing 
for 5 sec and 60°C extension for 4min. The sequencing reaction was washed using Montage 
SEQ96 Cleanup Kit (Millipore, Billerica MA, USA) and analyzed by the ABI 3730 DNA 
analyzer (Applied Biosystems Inc, Foster City, CA, USA).  
The final sequencing results were analyzed using the Contig Express program in Vector NTI 
Advance™ 10 (Invitrogen, Carlsbad, CA, USA) and the NCBI search program Nucleotide 
Blast 2 Sequences (http://blast.ncbi.nlm.nih.gov/bl2seq/wblast2.cgi) was used to compare the 
sequences to the expected GenBank DNA sequences. 
2.3 Mammalian cell techniques 
2.3.1 Cell line 
The HEK293T cell line used in this thesis was provided by American Type Tissue Culture 
(ATCC, Manassas, VA, USA). This cell line is virus transformed, and has human epithelial 
kidney origin. HEK293T cells were chosen for their properties of being easy to work with 
and highly transfectable using conventional techniques. In this thesis, HEK293T cells were 
used for transient transfection with expression vectors and microRNA oligo nucleotides 
supplied by Ambion (Applied Biosystems Inc, Foster City, CA, USA). 
2.3.2 Cell culturing and storage 
HEK293T cells were cultured in RPMI 1640 media with 25mM Hepes and L-glutamine 
(BioWhittaker®, Lonza, Verviers, Belgium) supplied with 10% GIBCO™ fetal bovine 
serum (FBS) (Invitrogen, Carlsbad, CA, USA). The cells were kept in an incubator with 5% 
CO2 and 37˚C. Cell work was carried out in a vertical laminar flow bench using sterile 
techniques.  
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The cells were grown in sterile flasks (Nunc™, Rochester, NY, USA) and diluted when 
reaching about 90% confluence. The media was removed and the cells were washed gently 
twice with Dulbecco‟s PBS (PAA Laboratories, Pasching, Australia). The cells were 
detached from the flask surface with GIBCO™ Trypsin (Invitrogen, Carlsbad, CA, USA) at 
37˚C for two minutes. Trypsin was inactivated with RPMI 1640 medium and the cells were 
harvested at 1000 x g for 5 minutes. The cells were diluted 1:20 or according to the next 
scheduled experiment. Generally, medium was changed every third day. 
Cells at a low passage number were stored in liquid nitrogen over longer time periods. 
Cultured cells were diluted to an approximate concentration of 1-2 x 10
6
 cells per ml and 
supplied with 10% of DMSO. The cells were frozen in cryo-tubes, stored at -80˚C overnight 
and transferred to a nitrogen tank. 
2.3.3 Cell quantification 
NucleoCounter (ChemoMetec A/S, Allerød, Denmark) was used for cell counting according 
to the manufacturer‟s instructions. Cells were lysed with a reagent A-100 which disrupts the 
plasma membrane in mammalian cells. A second reagent, stabilizing reagent B was used 
next to allow propidium iodide to stain DNA in the exposed nuclei. Equal amounts of the 
cell sample, reagent A and B were used. 50µl of the sample mixture was loaded into a 
nucleocasette and inserted into the NucleoCounter, which calculated the cell number based 
on the number of stained nuclei detected. 
2.3.4 Transient transfection of cell line HEK293T 
Transfection is a method used to introduce exogenous DNA into human cell lines. The 
method used utilizes lipids that form complexes with DNA. The lipid complexes enable 
import of foreign DNA into the cell, over the hydrophobic lipid membrane. Volumes and 
concentrations of reagents were as in the Lipofectamine™ 2000 protocol for DNA 
transfection (Invitrogen, Carlsbad, CA, USA). Master solutions were made to ensure equal 
distribution of Lipofectamine 2000™ (Invitrogen, Carlsbad, CA, USA) and DNA. 
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At day one, 1.6x10
5
 cells were plated out in each well in a 12 well tray. The second day, the 
transfection mixture was made. Lipofectamine™ 2000 (Invitrogen, Carlsbad, CA, USA) and 
appropriate amounts of DNA (1.6µg of vector and 1.56-100pmol of miRNA and SiRNA) 
were separately diluted in serum-free BioWhittaker® -media (Lonza, Verviers, Belgium). 
After five minutes of incubation, the DNA/media mixture was transferred to the tube 
containing the lipofectamine/media mixture and incubated at room temperature for 20 min. 
During the incubation, complexes of Lipofectamine 2000 and DNA were formed. The 
transfection mixtures were carefully dripped over the cells. The cells were incubated 
overnight at 37˚C and with 5% CO2. On the third day the cells were harvested for flow 
cytometry or visualized under UV-light. 
2.3.5 Cell harvest 
Cells were harvested prior to a flow experiment, 24 hours after transfection. The media was 
carefully removed and the cells were added appropriate amounts of PBS (PAA Laboratories, 
Pasching, Australia). After detachment of the cells with a pipette, the cells were collected by 
centrifugation at 6000 x g, 4°C for 5min, and resuspended in 350µl PBS. The cells were 
transferred to FALCON
® 
352063 tubes (BD Biosciences, Franklin Lakes, NJ USA) and kept 
on ice until analysis by Flow Cytometry. 
2.4 Flow cytometry 
Flow cytometry was used in this thesis to measure fluorescence intensity in HEK293T cells 
transfected with plasmids containing a gene encoding enhanced green fluorescent protein 
(EGFP). In short, the harvested (2.3.5) cells in suspension were sent through a sheath stream 
where cells were exposed to a laser beam (488nm). EGFP in the cytosol of the cells were 
excited by the monochromatic blue light and emitted green light at 530nm. The emitted 
fluorescent light was collected, spectrally filtered and enhanced by a photomultiplier tube in 
order to provide a value of the green fluorescence emitted (Nolan and Yang, 2007). For a 
schematic overview of the process, see Figure 2-1.  




Figure 2-1: Schematic overview of a typical flow cytometer. The cells (Red) in the sample are lined up in the 
sheath, one cell in diameter, with hydrodynamic focusing. The laser beam (blue), with a specific wavelength, 
hits one cell at the time and excites the fluorochromes. Scattered and emitted fluorescent light are filtered 
and collected by specific detectors and the gathered information is sent to a computer and analysed by an 
appropriate software program. 
2.4.1 The Instrument 
The flow cytometry experiments were carried out by Hans Christian Dalsbotten Aass at the 
Flow Cytometry Core Facility (http://www.ulleval.no/flow) at Oslo University Hospital, 
Ullevål. The cell samples were analysed using a FACS DiVa Vantage Cell Sorter (BD 
Biosciences, Franklin Lakes, NJ, USA) with a 488nm argon laser supplied with BD FACS 
DiVa software. For detection of emission through the FITC- (fluorescein isothiocynate) and 
PI- (propidium iodide) channels, the filters used were 530/30 and 630/22, respectively. A 
standard number of 10 000 events was recorded for every cell sample. 
2.4.2 Parameters and Plots 
To understand the plots, some important points need to be explained. First, the pulse 
registered from each cell as forward scatter (FSC), side scatter (SSC) and/or FITC (green 
fluorescent light) can be recorded as the pulse height (H), pulse area (A) or pulse Width (W) 
(see Figure 2-2). Each pulse is converted to a numerical value and plotted in histograms or 
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two dimensional dot plots (see Figure 2-3: each dot represents a numerical value of the 
parameters on the two axis). In general, forward scatter (FSC) may reflect the cell size and 
side scatter (SSC) reflect granularity of the cell interior. Second, the threshold for forward 
scatter area was set to a pulse value of 5000 to ignore and exclude small particles, small cells 
and debris that were not interesting in these experiments. An example is indicated by an 
arrow in Figure 2-3a. 
 
Figure 2-2: Plots visualizing the difference between Pulse- Height, Area and Width registered. Each pulse is 
converted to a numerical value of one of the three parameters. 
Another important point is that most cells have some natural auto fluorescent properties and 
can be plotted in the same plot as EGFP+ (transfected) cells. The FITC values are plotted 
against a biexponential (or “Logicle”) axis with a linear scale in the lower end and 
logarithmic scale in the upper end (Herzenberg et al., 2006). Cells recorded with very low or 
negative values of FITC can now be seen in the same plot as cells with high fluorescent 
intensity.  
2.4.3 Gating approach 
Gating is used to select the population of interest and exclude all other particles in the 
sample. In the beginning of the flow cytometry experiments in this thesis, a specific strategy 
for gating was used to ensure that the data recorded would in fact come from the cells of 
interest (HEK293T) and not from dead cells, debris or doublets. The following gating 
approach was used for all flow experiments carried out in this thesis to ensure that all 
experiments were done under the same conditions. 
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2.4.3.1 Determination of viable cells 
A transfected control sample (without DNA) of cells was added propidium iodide (PI) to 
determine dead cells (PI stains the nuclei in dead cells), and to be able to set the gate around 
the viable cell population. Dead cells that are small and have high granularity, can often be 
seen as cells with lower forward scatter area (FSC-A) and higher side scatter area (SSC-A) 
than viable cells. The viable cell population is indicated in blue in the FSC-A /SSC-A plot 
(Figure 2-3). The cells and debris gated away is indicated in as a purple (Figure 2-3) as a 
population displaying lower FITC than viable cells and with a partial overlap with the 
population defined as viable. Excluding dead cells was considered a crucial step of the gating 
process. 
 
Figure 2-3: Plots showing the gating of viable cells. a) The dead cells (purple), identified with PI staining, and 
other debris, were excluded when the gate was set to the viable population (Blue). The values plotted are side 
scatter area pulse (SSC-A) and forward scatter area pulse (FSC-A). The arrow indicates the threshold value set 
for FSC-A (5000) b) A histogram showing how dead cells and debris would have interfered with the results as a 
different population with partial overlap with the viable cells. The values plotted are number of cells (Count) 
and fluorescent intensity (FITC-A). 
2.4.3.2 Discrimination against Doublets 
Doublet‟s (two cells registered as one) can influence the measurements with false strong 
signals and were therefore gated away in a new plot. The doublets have a pulse area and 
pulse height equal to the singlets but will give an approximate double pulse width. The 
doublets were discriminated against, using the SSC-W. Viable singlets are seen inside the 
gate (blue) in the SSC-A/SSC-W plot (Figure 2-4). 




2.4.3.3 Determining EGFP levels in viable single cells. 
The control sample of cells transfected without DNA displayed low values of fluorescence. 
This population was gated and defined as EGFP negative (EGFP-) in the FITC-A/Count plot 
(Figure 2-5). Cells displaying higher fluorescens were defined as EGFP positive (EGFP+). 
 
Figure 2-5: Plots showing viable single cells and the results of the gating strategy. a) and b) showing a 
representative histogram and a two dimensional dot plot of a typical EGFP- control sample. b) and c) Showing 
the same plots from a representative cell sample with transfected with a pmiRPG vector (EGFP+). Blue colour 
represent cells defined as EGFP- and green colour represent EGFP+ defined cells. 
 
Figure 2-4: Plot showing only viable cells. 
The doublet’s (red) are recognized as cells 
with higher SSC-W than single cells (Blue). 
The singlets are gated and selected for 
further study. 
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The data plotted graphical in the result chapters is the mean value from the fluorescence 
intensity recorded from each cell as FITC-A or pulse area as described in section 2.4.2. The 
mean values were from viable, single EGFP positive cells.  
2.5 In Silico analysis 
Some of the most frequent used programs and software tools are listed and explained below. 
2.5.1 DNA manipulation 
- National Centre for Biotechnology Information NCBI (http://www.ncbi.nlm.nih.gov/) 
was used to search for GenBank DNA sequences. The BLAST 2 Sequences program 
(Blastn) was used to align two DNA sequences. 
- Primer 3 (http://frodo.wi.mit.edu/) and Net Primer (http://www.premierbiosoft.com/ 
netprimer/index.html) were used for primer design and quality check, respectively.  
- Vector NTI (Invitrogen, Carlsbad, CA, USA) was used as a tool to visualise plasmids 
with all the functional sequences. The program was also used to search for restriction 
sites in a vector and to analyse sequencing results using the “Contig Express” tool. 
- University of California Santa Cruz, UCSC (http://genome.ucsc.edu/) and Ensemble 
(http://www.ensembl.org/index.html) were used to search for gene positions in the 
genome and chromosomes. The Human BLAT Search (UCSC) was used to align 
known genomic sequences.  
2.5.2  miRNA databases 
miRNA databases were used to predict possible miRNA matches for the UTR sequences 
chosen for this study. The criteria for miRNA binding are however not yet fully understood. 
The various software tools available online use different algorithms (Sethupathy et al., 2006) 
to predict miRNA target interactions (Table 2-1) and consequently give search results that 
differ substantially. Five programs were chosen (Table 2-2) to compare and expand searches. 
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Table 2-1: Summary of the features used by some of the mammalian target prediction programs. Figure 
modified from Sethupathy et al. (2006). 
 
 
Table 2-2: miRNA target prediction programs used in this thesis. 
Program Website 
TargetScanS http://www.targetscan.org/  
miRanda http://www.microrna.org/microrna/getGeneForm.do  
Diana-microT http://www.diana.pcbi.upenn.edu/cgibin/miRGen/v3/Targets.cgi  
PicTar http://pictar.bio.nyu.edu/cgi-bin/PicTar_vertebrate.cgi  
miRBase http://microrna.sanger.ac.uk/cgi-bin/targets/v4/search.pl  
 
miRNAs predicted to target the selected UTR sequences, were purchased as small miRNA 
precursors Pre-miR™, which are partially double stranded RNAs that mimic endogenous 
precursor miRNAs, from Ambion
®
 (Applied Biosystems Inc, Foster City, CA, USA). 




3.1 Construction of reporter construct pmiRPG 
The miRNA binding site reporter vector pmiRPG was constructed (overview see Figure 3-1) 
from the plasmid pSiRPG (GenBank: DQ465352) an expression vector containing an EGFP 
encoding gene driven by a phosphoglycerate kinase (PGK) promoter (Størvold et al., 2007). 
The vector pSiRPG was digested (section 2.2.5), with the restriction enzyme EcoRI, ligated 
(section 2.2.8) and transformed (section 2.1.4) into E. coli. The structure of the obtained 
construct was verified using the restriction enzymes EcoRI, BamHI and HindIII and analyzed 
on an agarose gel (section 2.2.7) (Mona Lindeberg pers. com.). The resulting vector was 
named pRPG-1. 
 
Figure 3-1: Overview of the cloning steps leading to the reporter construct, pmiRPG. See text and Figure 3-2 
for detailed descriptions of the cloning steps. 
The next steps (Figure 3-2) included several rounds of PCR (section 2.2.10). The purpose 
was to introduce a 48bp sequence from the 3‟UTR of the luciferase reporter gene in the 
vector pMIR-REPORT™ Luciferase (Applied Biosystems Inc, Foster City, CA, USA). The 
sequence included the restriction site MluI that was unique in the new vector. Two primer 
sets were used in two separate PCR reactions. Two of the primers, pSiRPG-7167-Fwr and 




complementary to each other (indicated in blue in Figure 3-2). The two products, after the 
first rounds of PCR-reactions (PCR 1 and PCR 2), were mixed together. A second round of 
PCR was run with pBABEp4-Fwr and pSRPG-Rev to produce one fused PCR product using 
the two previous fragments as templates (Figure 3-2). This final PCR product was digested 
by EcoRI and BsiWI. The pRPG-1 vector was digested with the same two enzymes, and the 
vector fragment was purified from an agarose gel (section 2.2.3). Finally, the two fragments 
were ligated together and five colonies were selected randomly from the resulting 
transformation. Purified plasmids were digested in three separate reactions (MluI, HindIII 
and EcoRI + MluI). Analysis on an agarose gel revealed that four out of five clones had the 
expected fragment sizes (results not shown). Sequencing (section 2.2.11) with primer 
pmiRPG-5850-Fwr and pmiRPG-6136-Rev showed that the four clones contained the correct 
sequence. Clone 2 was chosen for further experiments and was named pRPG-2 (Figure 3-2).  
 
 
Figure 3-2: Overview of the PCR technique used to construct pRPG-2 by introducing new sequences into pRPG-
1: a) pRPG-1 was used as a template for two separate PCR reactions (PCR 1 and PCR 2) with primer pairs 
containing complementary tails (blue) with the new sequence .  b) The two PCR products were mixed together 
in a third PCR with the primers pBABEp4-Fwr and pSRPG-Rev. The two templates annealed to each other in 
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the complementary tails and the PCR resulted in one fragment c) pRPG-1 and the PCR fragment both were 
digested with EcoRI and BsiWI and ligated together. The final product was the vector pRPG-2. 
The MluI site in pRPG-2 was used to introduce unique restriction sites to make a functional 
multiple cloning site in the vector. Two complementary oligo nucleotides containing four 
restriction sites, MluI, ApaI, BglII and NotI were designed with identical overhangs (Figure 
3-3a) for ligation directly into a MluI digested vector. When this adapter oligo was ligated 
into the MluI digested vector, the MluI site in one end was restored.  In the other end the 
MluI site was not restored, due to incorrect nucleotides in the start of the site, designed to 
avoid two MluI sites in the vector (Figure 3-3).  
 
Figure 3-3: a) Adapter oligos ligated into vector pRPG-2. The two 5’-ends have identical overhangs with MluI 
digested DNA b) Sequenced pRPG-2 sequences showing the order of the new restriction sites ligated into the 
vector. 
Ligation reactions were made and transformed into E. coli. Nine colonies were randomly 
selected from the plate. The purified plasmids were digested using NotI and BglII restriction 
enzymes, both unique in the new multiple cloning site. The results showed that two of the 
clones (clone 4 and 9) were linearized with both enzymes indicating that the oligo adapter 
was inserted (Figure 3-4). Sequencing with primers pmiRPG-5850-Fwr and pmiRPG-6136-
Rev, verified that clone 9 had the oligo sequence inserted in the orientation shown in Figure 
3-3b. This final reporter construct for miRNA binding site evaluation was named pmiRPG 








3.2 Reporter constructs in pmiRPG 
3.2.1 Construction of pmiKRAS-3’U 
A construct with the 3‟UTR sequence from the KRAS gene was constructed in pmiRPG for 
use in experiments to verify the functionality of the expression vector and for use as a 
positive control for downregulation of gene expression by miRNAs. Kanamoto et al. (2006) 
showed that let-7 miRNA anneals to a sequence inside a 1500bp region of the 5kb KRAS 
3‟UTR. This region was cloned in the present work, and the primer sequences used were 
Figure 3-4: Gel picture showing DNA from 
nine clones digested with BglII (B), NotI (N) 
or undigested (-). Clone 4 and 9 were 
linearized with both enzymes. Selected 
fragment sizes in the 1kb size marker are 
indicated.  
 
Figure 3-5: The final reporter 
construct pmiRPG was used in 
further expression experiment 
and the 3’UTR sequence of 
selected genes were cloned  
into the multiple cloning site 
using MluI and NotI restriction 
sites. 
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modified from Kanamoto et al. (2006) by adding MluI and NotI restriction sites to the 
forward and the reverse primer, respectively (Appendix, Table 1).These primers (KRAS-
3’UTR-Fwr and KRAS-3’UTR-Rev) were used to amplify the KRAS 3‟UTR sequence from 
the cDNA of the breast cell line MCF-7 (provided by Mona M. Lindeberg). The PCR 
product was analyzed on an agarose gel, and the band of correct size was purified (section 
2.2.3). Another round of PCR was performed on the purified product to obtain higher purity 
and concentration, and the fragments were finally precipitated with ethanol (section 2.2.2). 
The KRAS 3‟UTR fragment was ligated into the pmiRPG vector after the digestion of both 
with the restriction enzymes NotI and MluI. The pmiRPG vector was digested with two 
enzymes in two separate tubes. After the first digest, samples from each reaction were 
analyzed on a 1% agarose gel to verify the linearization (digestion control). The linearized 
vector fragments were then digested with the second enzyme. The two vector samples 
digested twice were precipitated with isopropanol to purify the vector. 
The KRAS 3‟UTR fragment and the vector with complementary overhangs were ligated 
(section 2.2.8) with the T4 ligase (Roche™, Basel, Switzerland). The two vector samples 
(digested in different order) were ligated with the digested PCR fragment. Ligation controls 
were set up, one without the PCR fragment and one lacking both fragments and ligase. 
Additional controls were vectors digested only once, and the KRAS fragment digested twice. 
The ligation reactions were transformed into E. coli (Table 3-1). 
Table 3-1: Ligation setup and transformation results for the cloning of the selected KRAS 3’UTR sequence into 
reporter construct pmiRPG.  
 Ligation:     Transformation:     
Plate Vector Insert Ligase  DNA/50µl bacteria Vol. plated Colonies 
1 pmiRPG/NotI/MluI KRAS 3'UTR/NotI/MluI T4-ligase 15.0ng ¹⁄₂ 96 
2 pmiRPG/MluI/NotI KRAS 3'UTR/NotI/MluI T4-ligase 15.0ng ¹⁄₂ 39 
3 pmiRPG/NotI/MluI - T4-ligase 12.5ng ¹⁄₂ 23 
4 pmiRPG/NotI/MluI - - 12.5ng ¹⁄₂ 0 
5 pmiRPG/NotI - T4-ligase 12.5ng ¹⁄₂ 57 
6 pmiRPG/MluI - T4-ligase 12.5ng ¹⁄₂ 250 
7 KRAS 3'UTR/NotI/MluI - T4-ligase 12.5ng ¹⁄₂ 0 
8 pUC19-control - T4-ligase 0.25ng ¹⁄₁₀ 13 





The two ligations with KRAS-3‟UTR fragments and ligase, produced 96 and 39 colonies and 
the reaction with digested vector, with and without ligase produced 23 and 0 colonies. The 
three last control ligations, MluI digested and NotI digested vector and double digested 
fragments produced 57, 250 and 0 colonies respectively. Transformed pUC19 produced 13 
colonies and thereby reported a poor transformation frequency (5 x 10
5
 col/µg DNA). 
Comparisons between the two first ligations and ligation 3, revealed a slight increase in 
colonies when the PCR fragments were added to the reactions. Further comparison with the 
two first ligations and ligation 7 indicated that the double digested vector fragment was 
sufficiently digested in both ends. The results may indicate that the two first plates could 
contain positive clones. 
Twenty colonies from agar plate 1 and 2 were randomly selected and grown overnight 
(section2.1.2) and plasmids were purified from the overnight cultures (section2.2.1). An 
enzyme (BstEII) which cuts twice in the vector and not in the insert sequence was chosen for 
the first test digestion of the clones. Five clones gave the expected banding pattern after 
BstEII digestion, showing expected fragments for a vector with the new KRAS 3‟UTR 
sequence on the gel (results not shown).  
 
Figure 3-6: Gel picture showing five positive clones undigested (-), and digested with NotI (N) + MluI (M) and 
EcoRI (E). Selected fragment sizes in the 1kb size marker are indicated (left), and the expected fragments from 
digestion with indicated enzymes are listed (right).  
These clones were digested in a second experiment with MluI and NotI in the same reaction, 
to verify the 1.58kb fragment used, and with EcoRI that cuts once in the vector and once in 
the fragment, as a second control. All five clones showed the expected banding pattern after 
the two digestion experiments (Figure 3-6) and sequencing with primer pmiRPG-5850-Fwr 
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and pmiRPG-6136-Rev revealed that clone five contained the correct fragment (Figure 3-7). 
This clone was named pmiKRAS-3‟U.  
 
Figure 3-7: Clone 5 sequence (blue) sequenced with indicated primers and aligned with the KRAS (Black) gene 
sequence (GenBank: M54968). The KRAS-3’UTR sequence flank the enzyme sites (Red) in both sequences 
read. 
3.2.2 Construction of pmiCXXC4-3’U and pmiWDR79-3’U 
Reporter construct pmiCXXC4-3‟U and pmiWDR79-3‟U were constructed by insertion of 
the 3‟UTR sequences from the CXXC4 and the WDR79 gene into pmiRPG. The 136bp 
3‟UTR sequence from CXXC4 was amplified (section 2.2.10) from Human (Male) Genomic 
DNA (Promega, Madison, WI, USA) using a primer pair, CXXC4-3'UTR-Fwr and CXXC4-
3'UTR-Rev (Appendix, Table 1), designed to flank the entire 3‟UTR sequence and containing 
restriction sites for MluI and NotI in the tails. The short 3‟UTR sequence from WDR79 was 
purchased as complementary oligo nucleotide sequences designed to include five base pairs 
upstream and downstream of the 16bp UTR sequence, and with overhangs in the ends 
compatible with MluI and NotI restriction sites (Appendix, Table 2). 
The pmiRPG vector and the amplified UTR fragment from CXXC4 were digested with MluI 
and NotI and precipitated (section 2.2.2). The digested vector and the two UTR sequences 
were ligated together in separate reactions (section 2.2.8). Three control ligation reactions 
were made, one without the PCR fragments, one without ligase or fragments, and one with 




Table 3-2: Ligation setup and transformation results for the cloning of CXXC4 3’UTR and WDR79 3’UTR into 
reporter construct pmiRPG.  
  Ligation:     Transformation:     
 Plate Vector Insert Ligase  DNA/50µl bacteria Vol. plated Colonies 
1 pmiRPG/MluI/NotI CXXC4 3'UTR/NotI/MluI T4-ligase 26.9ng ¹⁄₂ 18 
2 pmiRPG/MluI/NotI  WDR79 Oligo seq. x 2 T4-ligase 25.8ng ¹⁄₂ 27 
3 pmiRPG/MluI/NotI - T4-ligase 25.0ng ¹⁄₂ 4 
4 pmiRPG/MluI/NotI - - 25.0ng ¹⁄₂ 0 
5 pmiRPG/MluI - T4-ligase 25.0ng ¹⁄₂ 93 
6 pUC19-control - T4-ligase 0.25ng ¹⁄₁₀ 5 




The two ligations with UTR fragments and ligase produced 18 and 27 colonies and the 
reaction with digested vector, with and without ligase produced 4 and 0 colonies. The vector 
only digested once by MluI produced 93 colonies and the transformed pUC19 control 
produced 5 colonies and thereby reported a poor transformation frequency (4 x 10
4
). 
Comparisons between the two first ligations and ligation 3, revealed an increase in colonies 
when the PCR fragments were added to the reactions. Comparisons between vector digested 
once and twice (ligation 3 and 5) indicated that the vector was sufficiently digested with both 
enzymes. The results indicated that the resulting agar plates from ligation with CXXC4 
fragment and WDR79 fragment could contain positive clones. 
Plasmid DNA from ten of the 18 colonies on agar plate number one was digested with 
restriction enzyme HindIII which cuts twice in the vector sequence. Four clones (clone 5, 8, 9 
and 10) gave the expected banding patter with HindIII and were digested in a second reaction 
with restriction enzymes NotI and MluI to visualise the fragment of correct size on the gel. 
Three of the four clones showed a fragment with a size corresponding to the 0,17kb expected 
from the CXXC4 3‟UTR (Figure 3-8a). 
 
Six colonies were selected randomly from agar plate number two (Table 3-2). Plasmids were 
purified (section 2.2.1) and digested with restriction enzymes NotI and MluI. 1.5µg of each 
clone were digested to obtain an amount of the oligo nucleotide sequence visible on a 2% 
agarose gel (approximately 7.5ng). The six clones showed a fragment with a size 
corresponding to the 0.037kb expected from WDR79 3‟UTR (Figure 3-8). 
 





Figure 3-8: Gel pictures from digestion experiments with potential positive CXXC4 3’UTR clones (a) and WDR79 
3’UTR clones (b). a) 1.5% Agarose gel showing the results of an undigested (-) control and clones digestion 
with NotI and MluI enzymes. Selected fragment sizes in the 10-0.1kb size marker are indicated. b) 2% Agarose 
gel showing the result of digestion with NotI and MluI enzymes. Selected fragment sizes in the pUC19/MspI 
size marker are indicated. The table shows the expected fragments for positive clones in the two experiments. 
Clone 5 from ligation 1, and clone 1 from ligation 2 (Table 3-2 and Figure 3-8) was 
sequenced (section 2.2.11) with primer pmiRPG-5850-Fwr and pmiRPG-6136-Rev to 
verifying that the correct UTR sequences from CXXC4 and WDR79 were inserted in the 
vectors, and the constructs were named pmiCXXC4-3‟U and pmiWDR79-3‟U (Appendix, 
Figure 2 and 3). 
3.2.3 Construction of pmiWWOX-3’U 
The construction of reporter construct pmiWWOX-3‟U from pmiRPG was carried out by 
inserting the 870bp 3‟UTR sequence from the gene WWOX into the MluI and NotI sites in 
pmiRPG. The construct from this cloning was sequenced with primer pmiRPG-5850-Fwr 
and pmiRPG-6136-Rev to confirm the presence of the WWOX 3‟UTR sequence (Appendix, 




3.3 Results from Flow Cytometry experiments 
The following sections presents results from flow cytometry analysis performed on 
transiently transfected HEK293T cells (section 2.3.4), using vectors expressing EGFP. All 
experiments were performed in duplicates, and the cells were analysed using flow cytometry 
as described in section 2.4.The gating strategy is described in section 2.4.3. 
3.3.1 EGFP expression from vectors 
The first experiment was carried out to ensure that the expression of EGFP in the vectors was 
not altered during the cloning steps. The cells were transfected with the three vectors, 
pSiRPG, pmiRPG and pmiWWOX-3‟U. The cells were analysed using flow cytometry after 
24 hours. The results obtained are presented in Figure 3-9.  
 
The results show the three vectors pSiRPG, pmiRPG and pmiWWOX-3‟U with EGFP 
expression (FITC) significantly above the normal auto fluorescence from the control sample 
(cells transfected without DNA). Although there were differences in the fluorescence 
intensity between the three vectors, showing pmiRPG with an average intensity of about the 
double of the intensities recorded from pSiRPG and pmiWWOX-3‟U, the expression 
functions of the vectors were shown to remain intact through the cloning steps and these 
constructs were used for further experiments. 
Figure 3-9: Plot showing fluorescent 
intensity (FITC) from cells transfected 
with pSiRPG, pmiRPG, pmiWWOX-3’U 
and no DNA (-) as indicated. The data 
plotted are Mean intensities (FITC-A) 
from cells defined as EGFP+. 
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3.3.2 Investigation of EGFP expression from pmiKRAS-3’U and 
regulation by Let-7a 
Two parallel experiments were carried out, to verify the EGFP expression from reporter 
construct pmiKRAS-3‟U, and to investigate the effect of miRNA let-7a on the expression of 
the vector. The cells were transfected with pmiKRAS-3‟U only, and pmiKRAS-3‟U 
cotransfected with 100pmol of siGFP Duplex (Thermo Scientific, Wilmington, De, USA) 
targeting the EGFP transcript (Appendix, Table 2) and 100pmol Let-7a miRNA. A cell 
sample transfected without DNA was included as a control. The cells were analysed using 
flow cytometry, after 24 hours (Figure 3-10). 
 
The flow cytometry results showed significant fluorescence from HEK293T cells transfected 
with the vector pmiKRAS-3‟U. The EGFP expression from cells cotransfected with 
pmiKRAS-3‟U and SiGFP-duplex was significantly down regulated, compared to the control 
cells transfected with pmiKRAS-3‟U (Figure 3-10). This result verified that siGFP-duplex 
targets the EGFP gene in the vector. Thus, the siGFP-duplex can be used in further 
experiments as a control for down regulation of the EGFP expression. The reduced EGFP 
expression in cells transfected with let-7a indicates down regulation of KRAS by Let-7a, as 
previous shown by others (Johnson et al., 2005).  
Figure 3-10: Plot showing fluorescent 
intensity (FITC) from cells transfected with 
pmiKRAS-3’U or no DNA (-) and cells 
cotransfected with pmiKRAS-3’U and 
SiGFP-duplex or Let-7a miRNA. The data 
plotted are Mean intensities from cells 





3.3.3 In Silico miRNA target prediction 
Five online miRNA target prediction programs (section 2.5.2) were used in combination to 
predict miRNAs that target the 3‟UTR sequences of the transcripts WWOX, CXXC4, and 
WDR79. The gene symbol/names were plotted into the programs and the human genome was 
selected for search of miRNAs. The programs showed a considerable variation in the 
miRNAs that they predicted and a decision was made to choose the miRNAs that were 
predicted by two or more programs. The miRNAs chosen for experiments in this thesis are 
listed in Table 3-3. 
Table 3-3: Overview of miRNAs selected for further study in this thesis. The miRNAs were predicted by two or 
more of the indicated programs, or selected for the reported conservation. Only one program predicted 
miRNAs for WDR79, and these miRNAs were both selected. 
Target Prog. miRNA Stem-loop miRNA Mature miRNA-Mature Sequence 5'-3' 
KRAS - hsa-let-7a-1 hsa-let-7a ugagguaguagguuguauaguu 
WWOX 1,2 hsa-mir-758 hsa-miR-758 uuugugaccugguccacuaacc 
 1 hsa-mir-516b-1 hsa-miR-516b* ugcuuccuuucagagggu 
 1,2 hsa-mir-134 hsa-miR-134 ugugacugguugaccagagggg 
CXXC4 1,2 hsa-mir-205 hsa-miR-205 uccuucauuccaccggagucug 
 1,2 hsa-mir-570 hsa-miR-570 cgaaaacagcaauuaccuuugc 
 1,2,4 hsa-mir-105-2 hsa-miR-105 ucaaaugcucagacuccuguggu 
 1,5 hsa-mir-532 hsa-miR-532-5p caugccuugaguguaggaccgu 
WDR79 1 hsa-mir-487a hsa-miR-487a aaucauacagggacauccaguu 
  1 hsa-mir-548d-2 hsa-miR-548d-3p caaaaaccacaguuucuuuugc 
The miRNAs listed are predicted by: TargetScanS1, miRanda2, Diana-microT3, PicTar4 and miRBase5 
3.3.4 Co-transfection of reporter constructs with miRNAs 
miRNA binding sites were predicted in the 3‟UTR of WWOX for the miRNAs hsa-miR-
516b*, hsa-miR-134 and hsa-miR-758 (Table 3-3). These miRNAs and let-7a, were used in 
an experiment, cotransfected with pmiWWOX-3‟U into HEK293T cells. 100pmol of each 
miRNA were used in the experiment. 
 Flow analysis 24 hours after transfection, revealed down regulation of the EGFP expression 
(FITC) in cells transfected with pmiWWOX-3‟UTR and the siGFP-duplex, compared to the 
control cells transfected with the vector only. The results also showed EGFP down regulation 
in cells transfected with the three predicted miRNAs and let-7a (Figure 3-11).  




Figure 3-11: Plot showing fluorescence intensity (FITC) from cells transfected with pmiWWOX-3’U or no DNA, 
and cells cotransfected with pmiWWOX-3’U and the four indicated miRNAs. The data plotted are Mean 
intensities from cells defined as EGFP+. 
This experiment needed an additional experiment to confirm that the miRNAs tested 
specifically downregulated WWOX 3‟UTR. The next experiment was designed with a wider 
selection of miRNAs and the miRNAs were added to the cell sample in two different 
amounts. One purpose of the new experiment was to investigate whether the reduction of the 
EGFP-signal from the cells cotransfected with miRNA was a result of specific down 
regulation, or a result of unspecific down regulation due to the concentration of miRNA used 
in the experiment (100pmol). 
The six miRNAs hsa-miR-516b*, hsa-miR-134, hsa-miR-758, hsa-miR-205, hsa-miR-578 
and hsa-miR-487a were cotransfected with pmiWWOX-3‟U into HEK293T. Two amounts 
of each miRNA were used, 100pmol and 25pmol. The cells were analysed by flow cytometry 
after 24 hours (Figure 3-12).  
The result showed that all six miRNAs down regulated the expression of EGFP with 
100pmol of added miRNAs. When the amount of miRNAs added was decreased to 25pmol, 
the repression decreased for five miRNAs while the last miRNA, miR-487a showed the 
repression as when 100pmol miRNA was used. 
In summary, the information from these experiments may indicate that unspecific regulation 
by miRNAs could be diminished with titration experiments to optimise the concentration of 




regulate the WWOX gene, and further that the three miRNAs predicted to regulate the WWOX 
gene, were false predictions. 
 
Figure 3-12: Plot showing fluorescence intensity (FITC) from cells transfected with pmiWWOX-3’U and cells 
cotransfected with pmiWWOX-3’U and indicated miRNAs in two amounts (100pmol and 25pmol). The data 
plotted are Mean intensities from cells defined as EGFP+. 
The experiment with the pmiWWOX-3‟UTR had raised important questions concerning the 
design of the experiments and in addition, there were still two expression vectors that 
remained unexplored in transfection experiments, the pmiCXXC4-3‟U and pmiWDR79-3‟U. 
The importance of exploring the fine tuning of the experiments led to the decision to leave 
the unexplored vectors and focus on the follow up of experiments already done with the 
pmiWWOX-3‟U vector and continue with this vector to optimize the experiments.  
3.3.5 Titration experiments may increase specificity 
Two separate titration experiments were carried out to optimize the miRNA amounts added 
in experiments where miRNAs were cotransfected with the reporter vector. The first 
experiment was done with pmiWWOX-3‟U cotransfected with two fold dilutions of let-7a 
starting at 100pmol per well. The cells were analysed with flow cytometry after 24 hours 
(Figure 3-13).The result showed an increase in EGFP expression with decreased let-7a 
concentration from 50pmol to 12.5pmol added.  




Two parallel experiments were designed to explore the consequence of even lower amounts 
of Let-7a cotransfected with pmiWWOX-3‟U. The experiments carried out similar to the 
previous experiment, but with four-fold dilutions of let-7 starting at 100pmol and ending at 
1.56pmol, gave the results shown in Figure 3-14. 
 
The results of the two experiments showed that all four amounts of let-7a lead to decreased 
EGFP signals in experiment 2, but variable results were obtained in experiment 1. Therefore, 
the optimal miRNA concentration where the miRNAs specifically targeting a transcript 
decrease the expression, and miRNAs that do not target the transcript give limited effect on 
the expression, was not found. The titration experiments may indicate that the method used 
to measure the EGFP expression in the experiments, should be investigated in order to obtain 
less variation between experiments. One possibility may be to increase the EGFP expression 
in the system, facilitating single cell expression measurements instead of the population 
based measurements used in this thesis (section 2.4.3.3). 
Figure 3-14: Plot showing 
fluorescent intensity (FITC) from 
cells in two separate experiments 
(experiment 1 and 2), transfected 
with pmiWWOX-3U and indicated 
amounts of Let-7a. The data 
plotted are Mean intensities from 
cells defined as EGFP+. 
 
Figure 3-13: Plot showing fluorescent 
intensity (FITC) from cells transfected 
with pmiWWOX-3U and Let-7a in the 
amounts indicated. The data plotted 






3.3.6 Comparison of promoter PGK and CMV in transient 
transfection 
 The vector pEGFP-N3 (GenBank: U57609), constructed with an EGFP gene expressed from 
the CMV (Human Cytomegalovirus) immediate early promoter (Muller et al., 1990), was 
chosen to compare the expression of EGFP from this strong promoter to EGFP expressed 
from the PGK promoter in pmiRPG. The EGFP gene sequences were identical in the two 
vector systems. 
HEK293T cells were transfected with pSiRPG, pmiRPG, pmiWWOX-3‟U and pEGFP-N3. 
The results from flow analysis after 24 hours (Figure 3-15) showed that the average 
fluorescence intensity in the cell population transfected with pEGFP-N3 was recorded to be 
about eight times higher than the intensity of the cells transfected with vectors with a PGK 
promoter. 
 
The difference in EGFP expression between the vector with PGK promoter compared to the 
pEGFP-N3 could be seen directly in the histograms from the flow experiments 
(representative examples shown in Figure 3-16), where the green part of the histogram 
Figure 3-15: Plot showing fluorescence 
intensity (FITC) from cells transfected with 
pSiRPG, pmiRPG and pmiWWOX-3’U 
containing the PGK promoter, and pEGFP-
N3 containing the CMV promoter. The data 
plotted are Mean intensities from cells 
defined as EGFP+. 
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indicate the EGFP positive cells, and blue indicate EGFP negative cells. 
 
  pSiRPG pmiRPG pmiWWOX-3'U pEGFP-N3 
% EGFP- 89.0 88.7 72.0 71.7 80.0 80.6 15.7 15.5 
% EGFP+ 11.0 11.3 28.0 28.3 20.0 19.4 84.3 84.5 
 
Figure 3-16: Representative histograms showing the results from flow analysis of HEK293T cells transfected 
with three vectors containing a PGK promoter (pSiRPG, pmiRPG and pmiWWOX-3’U), and one vector with a 
CMV vector (pEGFP-N3). Blue colour represent cells defined as EGFP negative and green colour represent 
EGFP positive cells. The fluorescence intensity (FITC-A) are plotted on a biexponential axis. The table shows 
the percentage distribution of cells in the EGFP positive or EGFP negative population for duplicate samples. 
The three histograms from cells transfected with vectors pSiRPG, pmiRPG and pmiWWOX-
3‟U had the majority of the cells in the population defined as EGFP-negative and assumed 
untransfected. In the histogram from the cells transfected with pEGFP-N3, the vector with 
CMV driven EGFP, the majority of the cells was shifted to the area defined as EGFP+, with 
a peak confined to the highest fluorescence intensity. 
The reason why the distribution of cells in the histograms differs substantially between the 
two vector systems could be that pSiRPG, pmiRPG and pmiWWOX-3‟U must be transfected 
into each cell in higher quantities than pEGFP-N3 to make the cells display a fluorescence 




pEGFP-N3 might give the cells fluorescence properties even in only a few copies and 
thereby seems to have a higher transfection efficiency compared to the three other vectors in 
this experiment. 
3.3.7 Analysis 24 and 48 hours after transfection 
The fluorescence intensity from expressed EGFP coded by reporter construct pSiRPG, 
pmiRPG, pmiWWOX-3‟U and pEGFP-N3 were investigated in an experiment where 
transfected cells were analysed 24 and 48 hours after transfection. Cells were plated at day 
one, and new cells were plated out on day two. The cells plated out on day one and two were 
transfected with the vectors on day two and three, respectively. The cells were analysed at 
the same time, day four, under the same conditions using flow cytometry, and the results are 
presented in Figure 3-17. 
 
 
The four vectors showed increased fluorescence intensities after 48 hours compared to 24 
hours. The expression from constructs containing the PGK promoter however, was still low 
compared to the pEGFP-N3 vector with CMV promoter after both 24 and 48 hours. The 
experiment showed that prolonged incubation time (from 24 to 48 hours) for cells transfected 
with expression vectors, did result in a modest increase of EGFP expression, but probably 
not enough to facilitate single cell expression measurements. The results may suggest that an 
exchange from PGK promoter to a CMV promoter could give better expression of the EGFP 
gene in the miRNA binding site reporter vectors. 
Figure 3-17: Plot showing 
fluorescence intensity (FITC) 
from cells transfected with 
pSiRPG, pmiRPG, pmiWWOX-
3’U and pEGFP-N3 and 
analyzed after 24 and 48 
hours. The data plotted are 
Mean intensities from cells 
defined as EGFP+. 
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3.3.8 Investigating constructs with PGK and CMV driven EGFP-
reporters 
Differences between the PGK- and the CMV promoter driven EGFP-gene were further 
investigated in an experiment where the three vectors pmiRPG, pmiWWOX-3‟U and 
pEGFP-N3 were cotransfected with siGFP duplex, hsa-miR-134 and the siGENOME Non-
Targeting siRNA#1 (Appendix, Table 3) that do not target any genes in the genome. The 
Non-Targeting siRNA#1 contain no significant sequence similarity to the EGFP gene. 
 
Figure 3-18: Plot showing fluorescence intensity (FITC) from cells transfected with pmiRPG, pmiWWOX-3’U 
and pEGFP-N3. The three vectors are also cotransfected with SiGFP-duplex, hsa-miR-134 and a non targeting 
siRNA. The data plotted are Mean intensities from cells defined as EGFP+. 
Again the results (Figure 3-18) showed a considerable higher EGFP expression from vectors 
containing the CMV promoter compared to the PGK promoter. The siGFP-duplex reduced 
the EGFP expression in cells transfected with all three vectors. The hsa-miR-134 and the non 
targeting siRNA reduced the signals from all three vectors significantly, which may indicate 





  - siGFP-duplex miR-134 Non-target siRNA 
% EGFP- 15.7 15.5 34.1 40.0 36.8 35.5 43.7 41.2 
% EGFP+ 83.3 84.5 65.9 60.0 63.2 64.5 56.3 58.8 
 
Figure 3-19: histograms showing the results from flow analysis of transfected HEK293T cells. The cells are 
transfected with pEGFP-N3 and cotransfected with the vector and siGFP-duplex, miR-134 miRNA and a non 
target siRNA. Blue colour represent cells defined as EGFP- and green colour represent EGFP+ defined cells. The 
fluorescence intensity (FITC-A) are plotted on a biexponential axis. 
Experiments with the pEGFP-N3 vector revealed that in contrast to the experiments carried 
out with the original vectors, the cells transfected with this vector showed a peak containing 
EGFP positive cells in the flow histogram indicated with an arrow in Figure 3-19 and Figure 
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3-20. In the samples cotransfected with miRNA/siRNA the cell population defined as EGFP 
negative had grown remarkably and could conceivably contain cells with an EGFP 
expression down regulated to a level that would define them as EGFP negatives.  
In summary, in this experiment there was a shift in the expression seen in the histograms; 
from cells transfected with the pEGFP-N3 vector, showing a peak of cells with high EGFP 
levels, to an increased number of EGFP negative cells when the cells were cotransfected with 
miRNA/siRNA. If the average intensity in the peak could be a measurement of EGFP 
expression of single cells in the experiment, and the shift could be a measure for 
miRNA/siRNA induced EGFP reduction, the precision of the flow cytometry experiments 
will be improved. Further experiments are required to assess if a change of promoter from 
PGK to CMV in the miRNA binding site reporter vectors will allow single cell 
measurement. 
 
  - siGFP-duplex 
% EGFP- 29.0 54.3 
% EGFP+ 71.0 45.7 
 
Figure 3-20: Representative histograms showed with reduced signal amplification, compared to the previous 
plots to look at the shape of the cell distributions. Theses plots can also be seen above in Figure 3-19. The 





MicroRNAs (miRNAs) are a relatively newly discovered class of small endogenous non 
coding RNA molecules with important roles in cell function and cancer development 
(Esquela-Kerscher and Slack, 2006; Mirnezami et al., 2009; Tong and Nemunaitis, 2008). 
miRNAs bind  to complementary sequences of mRNA transcripts and cleave the mRNA 
transcripts or inhibit translation (Tong and Nemunaitis, 2008). 
Grouping of tumor samples based on miRNA profiling has been shown to correlate with cell 
differentiation and development more accurately than mRNA expression profiling (Iorio et 
al., 2008), and analyses of miRNA expression have lead to suggestions for the use of 
miRNAs in cancer therapy (Esquela-Kerscher and Slack, 2006; Krutzfeldt et al., 2005; 
Meister et al., 2004; Meng et al., 2006; Slack and Weidhaas, 2006; Weiler et al., 2006). 
The binding properties between the target mRNA sequence and the miRNA however, are 
complicated and diverse (Bartel, 2004, 2009; Brennecke et al., 2005; Grimson et al., 2007; 
Krek et al., 2005; Lewis et al., 2003; Sethupathy et al., 2006), and the levels of regulation 
range from weak to a full switch effect (Flynt and Lai, 2008). The problems regarding 
miRNA target site prediction emphasize the importance of the constructions of systems for 
functional verification of the miRNA target sequences. 
In this thesis the aim was to construct a reporter vector system for cloning of 3‟UTR 
sequences and with EGFP as the reporter gene. Flow cytometry was chosen as the method 
for analysing the EGFP expression of cells cotransfected with the constructed reporter 
vectors and predicted miRNAs (section 1.5). 
4.1 The miRNA binding site reporter vector pmiRPG 
The miRNA binding site reporter vector pmiRPG was constructed from pSiRPG, encoding 
the EGFP protein, through several cloning- and PCR steps and with two intermediate 
constructs, pRPG-1 and pRPG-2. The vector pmiRPG contains a functional multiple cloning 
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site in the 3‟UTR sequence of the EGFP gene for cloning of 3‟UTR sequences from selected 
genes. 
The intermediates made in the vector construction process were verified with fragment 
analysis on agarose gels and with sequencing over the cloning junctions. The cloning 
junctions in the final construct pmiRPG were sequenced to verify the construct and to verify 
the orientation of the multiple cloning site (Figure 3-1 and Figure 3-3).  
The three vector constructs pSiRPG, pmiRPG and pmiWWOX-3‟U were analysed by flow 
cytometry after transient transfection into HEK293T cells. The results (Figure 3-9) showed 
that the three vectors displayed significant EGFP expression. This verified the reporter 
function of the pmiRPG constructs and indicated that cloning in the multiple cloning site of 
the pmiRPG vector did not disrupt the EGFP expression. The pmiRPG reporter vector 
constructed for expression studies, thereby seemed to be functional and suited for further 
experiments. 
4.2 Verification of four 3’UTR constructs. 
The three genes WWOX, CXXC4 and WDR79, were selected for the present study for their 
relations to cancer (section 1.4.2), and because they could potentially be candidates for 
miRNA regulation. KRAS was primarily selected as a positive control showing 
downregulation of the KRAS transcript by the let-7a miRNA (Johnson et al., 2005; 
Kanamoto et al., 2006). The 3‟UTR sequences from KRAS, WWOX and CXXC4 were 
amplified by PCR and cloned into the pmiRPG. The WDR79 3‟UTR sequence was designed 
as an oligo nucleotide sequence and ligated directly into the vector. The vector constructs 
with 3‟UTR sequences in pmiRPG as a fusion transcript with the EGFP gene, were 
sequenced over the cloning junctions to confirm the identity of each construct. The results 
from the sequencing analysis as shown in Figure 3-7 and in the Appendix, Figure 1-4, 
confirm that the four constructs contain the sequences from the transcripts KRAS, WWOX, 
CXXC4 and WDR79. Two of these constructs, pmiKRAS-3‟U and pmiWWOX-3‟U were 




4.3 Use of flow cytometry to measure EGFP expression in 
transfected cells 
Flow cytometry analysis was performed on HEK293T cells transiently transfected with the 
reporter constructs pSiRPG, pmiRPG, pmiKRAS-3‟U, pmiWWOX-3‟U and pEGFP-N3 
encoding EGFP, in order to distinguish successfully transfected cells from non transfected 
cells. The purpose was to record fluorescence intensities from only the cells containing the 
vectors. 
4.3.1 Flow cytometry detect decreased EGFP expression induced 
by siRNA 
The down regulation of KRAS expression by the miRNA let-7a  is well documented 
(Johnson et al., 2005; Kanamoto et al., 2006) and KRAS 3‟ UTR was included as a control in 
this thesis in order to verify the functionality of the vector system. To investigate whether the 
let-7a would give a detectable effect on the EGFP expression from the vector with a 3‟UTR 
sequence from the KRAS gene, this construct was cotransfected with a synthetic let-7a oligo 
nucleotide into HEK293T cells. 
In this experiment (Figure 3-10), the results showed that the EGFP expression from cells 
with pmiKRAS-3‟U resulted in fluorescence intensities significantly above that of the 
control cells, not containing a vector. When the siGFP-duplex that targeted the EGFP 
transcript in the vector directly, was cotransfected in the control experiment, EGFP 
expression was reduced significantly. This experiment showed that flow cytometry was 
suited to detect the decreased EGFP expression induced by the siRNA.  
When let-7a was cotransfected with the pmiKRAS-3‟U in this experiment, a significant 
reduction in EGFP expression was observed (Figure 3-10). The KRAS transcript has 
previously been documented to be regulated by let-7 (Johnson et al., 2005; Kanamoto et al., 
2006) and recent SNP (single nucleotide polymorphism) analysis of the let-7 target site in the 
KRAS 3‟UTR have revealed an increase in lung cancer risk (Chin et al., 2008) and reduced 
survival in oral cancers (Christensen et al., 2009). These observations provide more 
evidences concerning the let-7 regulation of the KRAS expression. However, because 
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negative control siRNA or miRNA were not included in the experiment in the current thesis, 
the specificity of this regulation cannot be judged in this study. 
4.3.2 All miRNAs tested result in decreased EGFP expression from 
pmiWWOX-3’U 
An experiment was carried out to test the hypothesis that miRNAs predicted to bind to and 
regulate the WWOX gene, would give an effect on the EGFP expression from the reporter 
vector pmiWWOX-3‟U. The four miRNAs let-7a, miR-516b*, miR-134 and miR-758 were 
cotransfected with pmiWWOX-3‟U into HEK293T cells and analyzed with flow cytometry. 
The three latter miRNAs, were predicted by the miRNA target prediction programs to bind to 
the WWOX-3‟UTR (section 3.3.3). 
The results revealed down regulation of the EGFP expression from the pmiWWOX-3‟UTR 
by all four miRNAs (Figure 3-11). The experiment may indicate that all four miRNAs 
regulate the WWOX gene, and there was no significant difference between the effect of the 
predicted and non predicted miRNA on the expression level. The results did however not 
rule out the possibility that the reduced level of expression recorded from the cotransfected 
cells could be caused by unspecific downregulation by the miRNAs.  
A larger selection of miRNAs was tested in a new experiment, against cotransfecting with 
the same vector pmiWWOX-3‟U. The miRNAs were added in two different concentrations 
to investigate if the wider selection of miRNAs would give the same downregulation as seen 
in the previous experiment, and to assay the effect of lowered miRNA concentration on the 
EGFP expression. 
All the six miRNAs used in the experiment gave similar down regulation of the EGFP 
expression when 100pmol miRNA was used (Figure 3-12). The comparison between the two 
amounts of miRNAs tested revealed that one miRNA, miR-487a downregulated the EGFP 
expression similarly for both miRNA concentrations used. The remaining miRNAs showed 
less efficient downregulation when the miRNA concentration decreased. These results might 
indicate that the miRNA miR-487a specifically downregulated the transcript, while the other 




concentration, and lost much of the effect when the miRNA concentration was reduced. 
However the results showed that there were significant downregulations of the expression by 
all the six miRNAs added in both concentrations. The results when decreased miRNA 
concentrations were used, showing reduced repression effects might indicate that the 
decrease in the EGFP expression was caused by unspecific downregulation by the miRNAs.  
The miR-487a gave interesting results concerning the regulation of pmiWWOX-3‟U in this 
experiment, and more experiments needs to be done to establish this miRNA as a true 
regulator of WWOX expression.  
4.3.3 Titration experiments indicate that improved signal recording 
methods are needed 
It was hypothesized that titration experiments could reveal a more optimal concentration of 
miRNAs where the miRNAs specifically targeting a transcript would decrease the expression 
of the reporter vector and miRNAs that do not target the transcript would show limited effect 
on the expression. The pmiWWOX-3‟U was chosen for the titration experiments, 
cotransfected with let-7a. This miRNA was not expected to target the WWOX 3‟UTR since it 
had not been predicted by the five miRNA target prediction programs. The hypothesis was 
therefore that successful titrations with let-7a would lead to a concentration where it would 
fail to repress the EGFP expression from pmiWWOX-3‟U. 
Three separate titration experiments were completed with cotransfection of pmiWWOX-3‟U 
and variable amounts of let-7a in attempts to reach the optimal amount of miRNAs, which 
would diminish unspecific regulation and show regulation of the EGFP expression from only 
the miRNAs that specifically target the 3‟UTR. 
The first experiment was carried out with four amounts of miRNAs in two fold dilutions 
from 100 – 12.5pmol and resulted in an increased EGFP expression at the lowest miRNA 
concentrations (Figure 3-13). Since all concentrations of miRNAs added in the experiment 
still repressed the EGFP expression, two new separate experiments were completed with four 
fold dilutions of miRNA down to 1.56pmol. The two experiments seen side by side in Figure 
3-14 differed substantially and failed to reveal any tendency concerning the effect of the 
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titrated miRNA amounts even when the results were inspected separately. The results from 
the titration Experiment 1, in the figure, even suggested an up regulation of the signal from 
let-7a added in two amounts, 25 and 6.5pmol.  
The results from these experiments could indicate that the method used to detect and present 
the expression levels in these experiments should be improved. The transfected cells did not 
show any distinct population (peak) apart from the untransfected cells in the flow 
experiments (representative histograms shown in Figure 3-16). Consequently the data used in 
this thesis are average intensity values from the cells showing fluorescence intensities that 
defines them as EGFP positive. This approach could allow influence from fluorescence 
background to affect the results. Transfected cells investigated under a microscope in UV-
light (results not shown) indicated that the pmiRPG-based vectors transfected into HEK293T 
cells gave weak EGFP expression from the cells compared to other EGFP coding vectors 
such as pEGFP-N3. Most of the cells transfected with pmiRPG-based vectors and viewed 
under the microscope displaying weak EGFP expression, were defined as EGFP negatives in 
the flow cytometry experiments. 
4.3.4 The CMV promoter effectively enhance the EGFP expression 
compared to a PGK promoter 
The fluorescence intensity from the pmiRPG vectors with an EGFP gene expressed from a 
PGK promoter was compared against pEGFP-N3 with the EGFP gene expressed from the 
strong CMV promoter. The EGFP gene sequences in the two vector systems are identical. 
The results showed an eight fold increase in the intensity from the pEGFP-N3 promoter 
compared to the three pmiRPG-based constructs (Figure 3-15). Comparisons of the flow 
histograms (representative histograms shown in Figure 3-16) revealed a difference in cell 
distributions in the sample with pEGFP-N3 transfected cells compared to cells transfected 
with pmiRPG-based constructs. The cells transfected with the PGK promoter based vector 
displayed low fluorescence intensities, and the dominant population of cells (70-90%) was 
found in the part of the histogram defined as EGFP negative. These cells displayed 
fluorescent intensities at the same level as untransfected cells. The cells transfected with the 








Considering that the four samples of cells were treated at the same time using the same 
protocol makes it tempting to assume that the transfection efficiency should be the same in 
the four cell samples. The reason why the distribution differs substantially between the two 
vector systems could therefore be that pSiRPG, pmiRPG and pmiWWOX-3‟U must be 
transfected into each cell in higher quantities than pEGFP-N3 to make the cells display a 
fluorescence intensity above the normal auto fluorescence and to define the cells as EGFP 
positive. pEGFP-N3 might give the cells fluorescence properties even when only a few 
vector copies are present. 
The observation from this experiment may suggest that the expression levels from the 
pmiRPG reporter vectors could be increased with an exchange of the promoter controlling 
the EGFP gene, to a stronger one, for example the CMV promoter explored in this 
experiment. A stronger expression could also reduce the influence from potential background 
noise and in that way improve the quality of the recordings. 
4.3.5 Prolonged incubation after transfection leads to a marginal 
increase in EGFP expression 
A hypothesis was made, that the recorded EGFP expression from the vectors could be 
increased if cells were analysed 48 hours after transfection. When the four vector constructs 
pSiRPG, pmiRPG, pmiWWOX-3‟U and pEGFP-N3 were transfected into HEK293T (Figure 
3-17), the EGFP levels were increased in the cells harvested after 48 hours. Even though the 
expression from the three PGK promoter based vectors showed increased expression after 
prolonged incubation, the expressions was still less than one third of the expression from 
pEGFP-N3 after 24 hours. In conclusion the increased time of incubation after transfection 
could not compensate for the less efficient EGFP expression from the PGK promoter. The 
CMV promoter seems to be more efficient and might be more suited for experiments where 
the fluorescence from EGFP is detected by flow cytometry. An exchange of the promoter in 
the pmiRPG constructs, could potentially give a better effect concerning the levels of the 
EGFP expression.  
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4.3.6 pEGFP-N3 transfected cells showed a “peak shift” after 
downregulation  
A new experiment was designed to test the hypothesis that cells with stronger EGFP 
expression after transfection with the pEGFP-N3 vector would show a distinct peak in the 
flow histogram. Parallel experiments with pmiRPG, pmiWWOX-3‟U and pEGFP-N3 
cotransfection with miRNA/siRNA were performed to investigate whether expression from 
pEGFP-N3 would be downregulation in a similar way as seen with pmiRPG-based vectors in 
previous experiments (Figure 3-10, Figure 3-11).This experiment was carried out with 
transfection of the three vector constructs and cotransfection with miR-134. The siGFP-
duplex used to downregulate the EGFP gene directly and the siGENOME Non-target 
siRNA#1 with no sequence similarity to the EGFP gene sequence, were used in parallel 
control experiments. 
The results showed down regulation of the expression from all three vectors in all 
cotransfection experiments with miR-134, siGFP-duplex and siGENOME Non-Target 
siRNA#1(Figure 3-18). The CMV promoter containing vector, pEGFP-N3 seemed to be a 
subject for unspecific downregulation in the same extent as the other two vectors in the 
experiment, however one could speculate that new titration experiments with this vector 
would be more successful because of the stronger expression. The enhanced expression 
would have less influence from background fluorescence and might give more answers about 
the optimal miRNA concentration than obtained until now. 
Histograms from the flow cytometry analysis of the pEGFP-N3 transfected cells (Figure 
3-19) revealed a shift from high- to low fluorescence intensity in the flow cytometry 
histogram after downregulation. When two of the samples were recorded with lower signal 
amplification (Figure 3-20), a small peak with high fluorescence intensity was revealed in the 
histogram from cells transfected with pEGFP-N3, and the majority of cells appeared to shift 
towards low intensity after downregulation of the signal with the siGFP-duplex, seen as a 
taller peak containing EGFP negative cells.  
The results obtained from this experiment suggested that stronger EGFP expression could 




positive cells shown by peaks in the histogram would make it easier to measure directly from 
this population and discard signals from other cells or background noise. If the peak shifts 
from high to low intensity in the plot after downregulation, this would be a direct visible 
effect in addition to the recorded values, and would facilitate using the average of the peak of 
EGFP positive cells directly as an estimate of EGFP expression in the transfected cells. 
4.4 Conclusion 
 A reporter construct pmiRPG was constructed, with EGFP as the reporter gene for 
incorporation of 3‟UTR sequences as fusion transcript with the EGFP gene. 
 3‟UTR sequences from the selected transcripts KRAS, WWOX, WDR79 and CXXC4 
were amplified or designed as oligos and cloned into the pmiRPG vector and verified 
with sequencing. 
 The EGFP expression from the constructs was verified after cloning in the multiple 
cloning site of pmiRPG. 
 All miRNAs/siRNAs, tested in this thesis, including a Non-Target siRNA, gave 
reduced EGFP expression. Further experiments need to be done to establish if this 
reduction results from unspecific regulation or inadequate recording methods. 
 The hsa-miR-487 gave reduced EGFP recordings with reduced miRNA 
concentrations in an experiment where hsa-miR-487 and reporter vector pmiWWOX-
3‟U were cotransfected into HEK293T cells. Additional experiments are required to 
establish this miRNA as a true regulator of WWOX expression. 
 The CMV promoter was shown to give increased EGFP expression compared to the 
vectors with PGK promoter. The CMV promoter could be inserted in the pmiRPG 
vector to enhance EGFP expression. 
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4.4.1 Suggestions for further work 
The results presented in this study indicate that the flow cytometry recordings after an 
exchange of promoter from a PGK- to a CMV-promoter in the pmiRPG might facilitate 
using the “peak shift” as seen in Figure 3-20 as an estimate of the miRNA knock down. This 
could be a better measure of knock down than the average values of intensities used in the 
experiments in this thesis. If a promoter exchange and new titration experiments gave 
satisfying results, the miRNA target prediction verification system could prove its value. 
Some important points could be followed in the extension of this thesis. 
 Exchange of the promoter driving the expression of the reporter gene EGFP in the 
pmiRPG vectors from PGK to CMV to achieve higher fluorescence intensities in 
flow cytometry experiments. This might result in distinct peaks of the EGFP positive 
cells and result in peak shifts during a downregulation of the signal. 
 Make stable transfected cell lines with pmiKRAS-3‟U and pmiWWOX-3‟U for 
titration experiments with let-7a in an attempt to reach an optimal miRNA 
concentration where only specific regulation influence the EGFP expression. 
 Use stably transfected cell lines for further experiments analyzing the effect of hsa-
miR-487 on the expression levels of pmiWWOX-3‟U to test whether this miRNA is 
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Table 1: Primer sequences 
Primers Sequence 5'-3' 
pBABEp4-Fwr agt tct tgc agc tcg gtg ac  
pSiRPG-7166-Rev tga aag ctg cgc act agt gag gga gct cat agg ccg gca tag acg cgt ttc ttc tga cac aac agt ctc 
pSiRPG-7167-Fwr acg cgt cta tgc cgg cct atg agc tcc ctc act agt gcg cag ctt tca tca agc tga tct gag tcc gg 
pSRPG-Rev gtc tct ccc cct tga acc tc  
pmiRPG-5850-Fwr  gac ttt cca cac ctg gtt gc 
pmiRPG-6136-Rev aca tgg tcc tgc tgg agt tc 
WWOX-3'UTR-Fwr aatt acg cgt gtg gag ctc aga gcg gat g 
WWOX-3'UTR-Rev aatt gcg gcc gcg ata ttc aag cat gtt ctt tta tta ag 
KRAS-3'UTR-Fwr aatt acg cgt gtt aca cca tct tca gtg cca g  
KRAS-3'UTR-Rev aatt gcg gcc gcc aca taa agg taa tta acc act ac  
CXXC4-3'UTR-Fwr aatt acg cgt gaa gca ttc cga tgg ttc tt 
CXXC4-3'UTR-Rev aatt gcg gcc gct tga aga aat ccc tat aca taa aat ga 
Table 2: Oligo nucleotide linker sequences 
Oligo sequences Sequence 5'-3' 
MABNB-1 cgc gtg ggc cca gat ctg cgg ccg cg  
BNBAM-2 cgc gcg cgg ccg cag atc tgg gcc ca  
WDR79-3'UTR-1 cgc gtt ata aaa agg ttt tta tga tac tag agc 
WDR79-3'UTR-2 ggc cgc tct agt atc ata aaa acc ttt tta taa 
Table 3: siRNA sequence/target sequence 
siRNA Sequence 5'-3'  
siGFP-duplex ggc tac gtc cag gag cgc acc (Target seq.) 






Table 4: Mature miRNA sequences 
miRNA Stem-loop miRNA Mature miRNA-Mature Sequence 5'-3' 
hsa-let-7a-1 hsa-let-7a uga ggu agu agg uug uau agu u 
hsa-mir-758 hsa-miR-758 uuu gug acc ugg ucc acu aac c 
hsa-mir-516b-1 hsa-miR-516b* ugc uuc cuu uca gag ggu 
hsa-mir-134 hsa-miR-134 ugu gac ugg uug acc aga ggg g 
hsa-mir-205 hsa-miR-205 ucc uuc auu cca ccg gag ucu g 
hsa-mir-570 hsa-miR-570 cga aaa cag caa uua ccu uug c 
hsa-miR-105-2 hsa-miR-105 uca aau gcu cag acu ccu gug gu 
hsa-miR-532 hsa-miR-532-5p cau gcc uug agu gua gga ccg u 
hsa-mir-487a hsa-miR-487a aauc aua cag gga cau cca guu 
hsa-miR-548d-2 hsa-miR-548d-3p caa aaa cca cag uuu cuu uug c 
 
Figure 1: pmiKRAS-3’UTR aligned against KRAS 
 
The aligned sequences correspond to the sequenced pmiKRAS-3‟U and the KRAS transcript 
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Figure 2: pmiCXXC4-3’UTR aligned against CXXC4 
 
The aligned sequences correspond to the sequenced pmiCXXC4-3‟U and the CXXC4 transcript 
(GenBank: NM_025212). The sequencing result is presented in bold, and the restriction sites are 
underlined. 
 
Figure 3: pmiWDR79-3’UTR aligned against WDR79 
 
The aligned sequences correspond to the sequenced pmiWDR79-3‟U and the WDR79 transcript 






Figure 4: pmiWWOX-3’UTR aligned against WWOX 
 
The aligned sequences correspond to the sequenced pmiWWOX-3‟U and the WWOX transcript 
(GenBank: AF211943). The sequencing result is presented in bold, and the restriction sites are 
underlined. 
Vector constructs used directly or indirectly in the thesis 
Figure 5: pSiRPG 
 
The expression vector pSiRPG (Størvold et al., 2007) was used as the vector backbone in the 
construction of pmiRPG. 
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Figure 6: pMIR-REPORT Luciferase 
  
A sequence from the luciferase based reporter vector pMIR-REPORT (Applied Biosystems Inc, 
Foster City, CA, USA) was cloned into pmiRPG during one of the cloning steps. 
Figure 7: pEGFP-N3 (GenBank U57609) 
 
The construct pEGFP-N3 (Becton Dickinson, Rutherford, NJ,USA) has  an EGFP gene behind the 
immediate early promoter CMV, and was used in experiments to study the fluorescence intensity 
from expressed EGFP in transfected cells. 
